徳島大学 / 教育研究者総覧 --- 布川朋也

専門分野

研究テーマ

著書・論文

著書:

1.	山本恭代, 大豆本圭, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 膀胱への穿通胎盤にて帝王切開，子宮全摘，膀胱部分切除術施行後に骨盤内尿腫を形成し，真性尿失禁をきたした1例, 2018年10月.
2.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 間質性膀胱炎が疑われ，膀胱水圧拡張術が診断の契機となった膀胱アミロイドーシスの1例, 2017年12月.

学術論文(審査論文):

1.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa and Hiroomi Kanayama : Assistent guide short: A new device for facilitating ureteric stenting in women., International Journal of Urology, 2023. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/iju.15252 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37504506 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165960914 (DOI: 10.1111/iju.15252, PubMed: 37504506, Elsevier: Scopus)
2.	Yutaro Sasaki, Kei Daizumoto, Kyotaro Fukuta, Keito Shiozaki, Mitsuki Nishiyama, Seiya Utsunomiya, Saki Kobayashi, Kosuke Seto, Yoshiteru Ueno, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Ryoichi Nakanishi, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Masayuki Takahashi : Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery., Asian Journal of Endoscopic Surgery, 2023. (要約) This study was performed to evaluate the safety and efficacy of lymph node dissection (LND) during robot-assisted radical cystectomy (RARC) compared with open radical cystectomy (ORC). From October 2003 to December 2021, 122 patients underwent LND during RARC and 103 patients underwent LND during ORC at Tokushima University Hospital and Tokushima Prefectural Central Hospital. We investigated the safety and efficacy of LND during RARC by comparing the surgical and oncological outcomes between the two groups. The patients were significantly older in the RARC than the ORC group. The operative time was significantly shorter and the estimated blood loss was significantly lower in the RARC than the ORC group. Although the lymph node yield was significantly higher in the RARC than the ORC group, there was no significant difference in lymph node positivity between the groups. There was no significant difference in the incidence of local recurrence or distant metastasis between the two groups. The 5-year survival rates (overall survival, cancer-specific survival, and recurrence-free survival) were not different between the RARC and ORC groups. This study suggests that the surgical and oncological safety and efficacy of LND during RARC are greater than those of LND during ORC. We believe that LND during RARC is a higher-quality procedure than LND during ORC. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/ases.13234 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37489628 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165549223 (DOI: 10.1111/ases.13234, PubMed: 37489628, Elsevier: Scopus)
3.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Yoshimi Bando, Minoru Kowada, Tsogt-Ochir Dondoo, Yutaro Sasaki, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hisanori Uehara and Hiroomi Kanayama : Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma., British Journal of Cancer, 2023. (要約) Decreased INSR in RCC could be a biomarker to predict axitinib resistance. Regarding the resistant mechanism, vascular endothelial cells with decreased INSR in RCC may secrete interferon-β and induce PD-L1. (出版サイトへのリンク) ● Publication site (DOI): 10.1038/s41416-023-02325-8 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37355721 ● Search Scopus @ Elsevier (PMID): 37355721 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-023-02325-8 (DOI: 10.1038/s41416-023-02325-8, PubMed: 37355721)
4.	Katsuhito Hori, Yutaro Sasaki, Keito Shiozaki, Fumiya Kadoriku, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Yoshihiro Tsuruo and Hiroomi Kanayama : Efficacy of fresh-frozen cadaveric surgical training for arteriovenous fistula in vascular access., The Journal of Vascular Access, 2023. (要約) Twelve CST sessions were performed on nine FFCs. All training sessions allowed completion of AVF creation with a median operative time of 78.5 min. Although veins and arteries were more difficult to identify than in a living body, other surgical operations could be performed in the same way as in a living body. All the respondents stated that it was good for them to experience CST. In addition, 86% of surgeons responded that CST improved their surgical techniques, and 71% of surgeons responded that they were less anxious about AVF creation. (出版サイトへのリンク) ● Publication site (DOI): 10.1177/11297298231169056 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37070175 ● Search Scopus @ Elsevier (PMID): 37070175 ● Search Scopus @ Elsevier (DOI): 10.1177/11297298231169056 (DOI: 10.1177/11297298231169056, PubMed: 37070175)
5.	Yutaro Sasaki, Masayuki Takahashi, Kyotaro Fukuta, Keito Shiozaki, Kei Daizumoto, Yoshiteru Ueno, Ryotaro Tomida, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Hiroomi Kanayama : Assistent guide: A novel device for ureteral stent placement in robot-assisted intracorporeal ileal conduit., The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS, Vol.19, No.4, 2023. (要約) We showed the safety and efficacy of the Assistent guide for ureteral stent placement in RICIC. (キーワード) Humans / Cystectomy / ロボティクス (robotics) / Urinary Diversion / Stents / Ureteral Obstruction / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.1002/rcs.2513 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36840720 ● Summary page in Scopus @ Elsevier: 2-s2.0-85149381419 (DOI: 10.1002/rcs.2513, PubMed: 36840720, Elsevier: Scopus)
6.	Kunihisa Yamaguchi, Keisuke Ozaki, Tomoya Fukawa, Yutaro Sasaki, Shu Wakino and Masayuki Takahashi : Drug-induced de novo thrombotic microangiopathy diagnosed 2 years after renal transplantation: A case report and literature review, Renal Replacement Therapy, Vol.9, 1-6, 2023. (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s41100-022-00453-0 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1186/s41100-022-00453-0 (DOI: 10.1186/s41100-022-00453-0)
7.	Keisuke Ozaki, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Megumi Tsuda, Takayuki Uchida, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 80-87, 2023. (要約) Nutritional status of mRCC patients may predict changes in body composition and be associated with their prognosis. J. Med. Invest. 70 : 80-87, February, 2023. (キーワード) Humans / Carcinoma, Renal Cell / Kidney Neoplasms / Nutritional Status / Prognosis / Body Composition / Retrospective Studies / Protein Kinase Inhibitors (徳島大学機関リポジトリ) ● Metadata: 118311 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.80 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164748 ● Search Scopus @ Elsevier (PMID): 37164748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.80 (徳島大学機関リポジトリ: 118311, DOI: 10.2152/jmi.70.80, PubMed: 37164748)
8.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (要約) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (キーワード) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.21873/invivo.13136 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
9.	尾﨑啓介, 山口邦久, 多田亜沙香, 布川朋也, 佐々木雄太郎, 楠原義人, 山本恭代, 林秀樹, 高橋正幸, 鶴尾吉宏, 橋本寛文, 金山博臣 : 未固定凍結遺体を用いた心停止下献腎摘出教育の試み, 日本臨床腎移植学会雑誌, Vol.10, No.2, 259-261, 2022年.
10.	Keito Shiozaki, Kazuyoshi Izumi, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Yasuo Kawanishi and Hiroomi Kanayama : Comparison of robot-assisted partial nephrectomy with soft coagulation and double-layer technique for complex and non-complex tumors., International Journal of Urology, Vol.30, No.3, 281-288, 2022. (要約) Single-layer suturing with soft coagulation achieves renal function and perioperative outcomes comparable to those of double-layer suturing regardless of complexity. (キーワード) Humans / Robotics / Retrospective Studies / Nephrectomy / Kidney / Kidney Neoplasms / Robotic Surgical Procedures / Treatment Outcome (徳島大学機関リポジトリ) ● Metadata: 118156 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/iju.15112 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36448456 ● Search Scopus @ Elsevier (PMID): 36448456 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.15112 (徳島大学機関リポジトリ: 118156, DOI: 10.1111/iju.15112, PubMed: 36448456)
11.	Fumiya Kadoriku, Yutaro Sasaki, Kyotaro Fukuta, Yuichiro Atagi, Keito Shiozaki, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yutaka Yanagihara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Sadamu Yamashi, Masaharu Kan and Hiroomi Kanayama : A propensity score matching study on robot-assisted radical cystectomy for older patients: comparison of intracorporeal ileal conduit and cutaneous ureterostomy., BMC Urology, Vol.22, No.1, 2022. (要約) The median age was lower in the ICIC group compared with the CUS group, and the proportion of high-risk cases (ECOG-PS ≥ 2 or ASA-PS ≥ 3) did not differ. The median operation time was longer in the ICIC group, and estimated blood loss was higher, compared with the CUS group. There were no significant differences in the incidence of complications within the first 30 postoperative days, incidence of complications 30-90 days after surgery, 2-year overall survival, 2-year cancer-specific survival, and 2-year recurrence-free survival. The stent-free rate was significantly lower in the CUS group than that in the ICIC group. (キーワード) Aged / Humans / Cystectomy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / ロボティクス (robotics) / Treatment Outcome / Ureterostomy / Urinary Bladder Neoplasms / Urinary Diversion (徳島大学機関リポジトリ) ● Metadata: 118559 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12894-022-01123-3 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36344965 ● Summary page in Scopus @ Elsevier: 2-s2.0-85141380657 (徳島大学機関リポジトリ: 118559, DOI: 10.1186/s12894-022-01123-3, PubMed: 36344965, Elsevier: Scopus)
12.	Kazutoshi Fujita, Go Kimura, Toyonori Tsuzuki, Taigo Kato, Eri Banno, Akira Kazama, Ryo Yamashita, Yuto Matsushita, Daisuke Ishii, Tomoya Fukawa, Yuki Nakagawa, Tamaki Fukuyama, Fumikazu Sano, Yukihiro Kondo and Hirotsugu Uemura : The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis., Cancers, Vol.14, No.21, 2022. (要約) Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis. (徳島大学機関リポジトリ) ● Metadata: 118574 (出版サイトへのリンク) ● Publication site (DOI): 10.3390/cancers14215258 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36358675 ● Search Scopus @ Elsevier (PMID): 36358675 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers14215258 (徳島大学機関リポジトリ: 118574, DOI: 10.3390/cancers14215258, PubMed: 36358675)
13.	Kouki Tada, Kei Daizumoto, Masayuki Takahashi, Hisanori Uehara, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment., IJU Case Reports, Vol.6, No.1, 41-44, 2022. (要約) The patient was a 65-year-old man who underwent open nephrectomy for RCC. After the nephrectomy, he had recurrences several times, and metastasectomy had been performed for each recurrence. At 13 years after the nephrectomy, multiple liver, and lung metastases appeared. The treatment was switched to axitinib, followed by cabozantinib, then nivolumab. The best response was PR, SD, and PD for these three drugs, and treatment duration was 14, 3, and 3 months, respectively. As the fifth line, sunitinib was administered, with significant shrinkage of the multiple liver metastases, and PR has been maintained for 34 months. (徳島大学機関リポジトリ) ● Metadata: 118791 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/iju5.12545 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36605682 ● Search Scopus @ Elsevier (PMID): 36605682 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12545 (徳島大学機関リポジトリ: 118791, DOI: 10.1002/iju5.12545, PubMed: 36605682)
14.	ANAYT ULLA, Kanae Osaki, Mizanur Md Rahman, Reiko Nakao, Takayuki Uchida, Isafumi Maru, Kazuaki Mawatari, Tomoya Fukawa, Hiro-omi Kanayama, Iori Sakakibara, Katsuya Hirasaka and Takeshi Nikawa : Morin improves dexamethasone-induced muscle atrophy by modulating atrophy-related genes and oxidative stress in female mice., Bioscience, Biotechnology, and Biochemistry, Vol.86, No.10, 1448-1458, 2022. (要約) This study investigated the effect of morin, a flavonoid, on dexamethasone-induced muscle atrophy in C57BL/6J female mice. Dexamethasone (10 mg/kg body weight) for 10 days significantly reduced body weight, gastrocnemius and tibialis anterior muscle mass, and muscle protein in mice. Dexamethasone significantly upregulated muscle atrophy-associated ubiquitin ligases, including atrogin-1 and MuRF-1, and the upstream transcription factors FoxO3a and Klf15. Additionally, dexamethasone significantly induced the expression of oxidative stress-sensitive ubiquitin ligase Cbl-b and the accumulation of the oxidative stress markers malondialdehyde and advanced protein oxidation products in both the plasma and skeletal muscle samples. Intriguingly, morin treatment (20 mg/kg body weight) for 17 days effectively attenuated the loss of muscle mass and muscle protein and suppressed the expression of ubiquitin ligases while reducing the expression of upstream transcriptional factors. Therefore, morin might act as a potential therapeutic agent to attenuate muscle atrophy by modulating atrophy-inducing genes and preventing oxidative stress. (キーワード) Animals / Body Weight / Dexamethasone / Female / Flavones / Malondialdehyde / Mice / Mice, Inbred C57BL / Muscle Proteins / Muscle, Skeletal / Muscular Atrophy / Oxidative Stress / Tripartite Motif Proteins / Ubiquitin-Protein Ligases (出版サイトへのリンク) ● Publication site (DOI): 10.1093/bbb/zbac140 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35977398 ● Search Scopus @ Elsevier (PMID): 35977398 ● Search Scopus @ Elsevier (DOI): 10.1093/bbb/zbac140 (DOI: 10.1093/bbb/zbac140, PubMed: 35977398)
15.	Kyotaro Fukuta, Keito Shiozaki, Ryoichi Nakanishi, Hirofumi Izaki, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Leptomeningeal carcinomatosis in small cell carcinoma of the prostate., IJU Case Reports, Vol.5, No.6, 493-496, 2022. (要約) A 69-year-old man visited our hospital due to dysuria and edema. Bilateral hydronephrosis and lymph node metastases due to a pelvic tumor were observed. Although the prostate-specific antigen level was normal, the tumor was suspected to originate from the prostate. He underwent percutaneous nephrostomy and prostate biopsy. Histopathology revealed small cell carcinoma accompanied by increased pro-gastrin-releasing peptide and neuron-specific enolase levels. After receiving systemic chemotherapy with carboplatin and etoposide and radiation therapy for prostate, these lesions gradually decreased in size, and tumor markers normalized. Ten months after the initial diagnosis, he developed consciousness disorder and seizure. Magnetic resonance imaging revealed leptomeningeal carcinomatosis without any other recurrences and elevated tumor markers. He died 4 weeks after these symptoms appeared. (徳島大学機関リポジトリ) ● Metadata: 118792 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/iju5.12524 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36341201 ● Search Scopus @ Elsevier (PMID): 36341201 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12524 (徳島大学機関リポジトリ: 118792, DOI: 10.1002/iju5.12524, PubMed: 36341201)
16.	K. Ozaki, Takashi Kawanaka, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Appropriate management reduces radiation exposure in daily urological practice, International Journal of Urology, 2022. (要約) To identify and raise awareness of the radiation exposure of urologists due to X-ray fluoroscopic procedures in daily practice. This was a single-center, cohort study of 30 consecutive patients who underwent periodic percutaneous or transurethral replacements of urinary tract catheters. A total of 55 replacements every 3 months with cases aligned were performed by a single urologist. The urologist's radiation exposure and the incident dose to patients per case were measured with thermoluminescent dosimeters. In the latter 3-month period, the pulse fluoroscopy condition was changed from 15 to 7.5 pulses per second, and collimation was added to the field of view. In the analysis of all patients, the use of a modified pulse rate and collimation did not affect the fluoroscopy time, but it did significantly reduce the air kerma and dose area product; in addition, with respect to the medical exposure dose during percutaneous catheter replacement, fluoroscopy time was longer, but air kerma and dose area product showed significant decreases. As with decreases in medical exposure of patients, the equivalent dose for eye lenses of the urologist decreased from 1.2 mSv in the first 3-month period to 0.2 mSv in the second 3-month period. Similarly, the exposure dose for the extremities also decreased significantly, from 33.9 mSv to 8.1 mSv. Urologists are exposed to non-negligible amounts of radiation due to fluoroscopy. Appropriate management such as modified pulse fluoroscopy condition and precautions are required. (徳島大学機関リポジトリ) ● Metadata: 118219 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/iju.14971 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35851694 ● Search Scopus @ Elsevier (PMID): 35851694 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.14971 (徳島大学機関リポジトリ: 118219, DOI: 10.1111/iju.14971, PubMed: 35851694)
17.	Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto and Hiro-omi Kanayama : Efficacy of the Mercedes-Benz closure technique for vaginal reconstruction in female robot-assisted radical cystectomy, Asian Journal of Endoscopic Surgery, 2022. (要約) Vaginal reconstruction using the posterior vaginal wall is required following radical cystectomy in women with resection of the uterus, adnexa, and anterior vaginal wall. Roll closure and clamshell closure are two widely known techniques. Of these, clamshell closure is recommended because roll closure has a high likelihood of breakdown or a resultant canal that is too narrow for sexual intercourse. In clamshell closure, however, folding the posterior vaginal wall anteriorly can be difficult. Therefore, we devised Mercedes-Benz closure, in which the vaginal wall is sutured from three directions to form a Mercedes-Benz shape, for anastomosis without tension on the vaginal wall. The present study was performed to investigate the efficacy of this alternative surgical technique for vaginal reconstruction. Twenty-six patients who underwent vaginal reconstruction following robot-assisted radical cystectomy were divided into two groups: 15 underwent clamshell closure and 11 underwent Mercedes-Benz closure. The patients' characteristics and surgical outcomes were compared between the two groups. There were no significant differences in clinical characteristics, including age, body mass index, and prior abdominal surgery between the two groups. The median vaginal reconstruction time tended to be longer in the Mercedes-Benz closure group than in the clamshell closure group (35.0 vs. 27.0 min, p = 0.102). No complications associated with vaginal reconstruction were identified. The surgical outcomes were comparable between Mercedes-Benz closure and clamshell closure. If vaginal reconstruction with clamshell closure is difficult, Mercedes-Benz closure is a valuable alternative technique. (出版サイトへのリンク) ● Publication site (DOI): 10.1111/ases.13109 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35842843 ● Search Scopus @ Elsevier (PMID): 35842843 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.13109 (DOI: 10.1111/ases.13109, PubMed: 35842843)
18.	深谷友祐, 大豆本圭, 角陸文哉, 山本拓, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣, 仁木真理子, 上原久典 : イピリムマブ・ニボルマブ併用療法が著効した乳頭状腎細胞癌の1例, 泌尿器科紀要, Vol.68, No.4, 107-111, 2022年. (要約) We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained. (キーワード) Papillary renal cell carcinoma / Ipilimumab and nivolumab / 494.9 (出版サイトへのリンク) ● Publication site (DOI): 10.14989/actauroljap_68_4_107 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390573715168780160 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_4_107 (DOI: 10.14989/actauroljap_68_4_107, CiNii: 1390573715168780160)
19.	Kyotaro Fukuta, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient, Case Reports in Oncology, Vol.15, No.1, 462-468, 2022. (要約) The micropapillary variant of urothelial carcinoma (MPUC) is an aggressive form of urothelial carcinoma with high metastatic potential and a poor prognosis. Although various therapies have been reported, there is still no established treatment strategy for MPUC due to its rarity. The incidence of urinary tract malignancies is higher in patients undergoing hemodialysis (HD) than in healthy individuals. Here, we report the case of an 82-year-old man on HD with end-stage kidney disease who visited our hospital for macrohematuria. Cystoscopy followed by computed tomography and urine cytology revealed a sessile papillary tumor around the left bladder wall. We performed transurethral resection of the bladder tumor. Based on histopathological and imaging findings indicative of clinical-stage T3N0M0 MPUC, we performed radical cystectomy. Histopathology revealed a pathological stage T4aN0M0 MPUC. Two months after the cystectomy, the patient complained of constipation and painful defecation due to local recurrence and rectal invasion. While colostomy was performed to improve defecation 3 months after cystectomy, he did not receive any chemotherapy due to his progressively worsening general condition. Six months after cystectomy, he died following rapid metastases. Our findings, in this case, confirm that bladder cancer in HD patients tends to be pathologically more advanced. Therefore, regular screening is recommended for its early detection in HD patients. (徳島大学機関リポジトリ) ● Metadata: 117427 (出版サイトへのリンク) ● Publication site (DOI): 10.1159/000524430 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35702563 ● Search Scopus @ Elsevier (PMID): 35702563 ● Search Scopus @ Elsevier (DOI): 10.1159/000524430 (徳島大学機関リポジトリ: 117427, DOI: 10.1159/000524430, PubMed: 35702563)
20.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men, Journal of Robotic Surgery, Vol.16, No.2, 437-444, 2022. (要約) The influence of the console surgeon on the feasibility and outcome of various robot-assisted surgeries has been evaluated. These variables may be partially affected by the skills of the patient-side surgeon (PSS), but this has not been evaluated using objective data. This study aimed to describe the surgical techniques of the PSS in robot-assisted radical cystectomy (RARC) and intracorporeal ileal conduit (ICIC) urinary diversion and objectively examine the changes in surgical outcomes with increasing PSS experience. During a 3-year period, 28 men underwent RARC and ICIC urinary diversion. Clinical characteristics and surgical outcomes were compared between patients who underwent surgery early (first half group) or late in the study period (second half group). The pre-docking incision enabled easy specimen removal. The glove port technique widened the working space of the PSS. The stay suture allowed the PSS to control the distal portion of the conduit, facilitating the passage of the ureteral stents. During stoma creation, pneumoperitoneum pressure was lost by opening the abdominal cavity. To overcome this problem, the robotic arm was used to lift the abdominal wall to maintain the surgical field and facilitate the PSS procedure. Compared with the first half group, the second half group had significantly shorter times for urinary diversion (202 min vs 148 min, p < 0.001), ileal isolation and anastomosis (73 min vs 45 min, p < 0.001), and stenting (23.0 min vs 6.5 min, p < 0.001). As the experience of the PSS increased, the time of the PSS procedures decreased. (キーワード) Cystectomy / Humans / Male / Robotic Surgical Procedures / Robotics / Surgeons / Treatment Outcome / Urinary Bladder Neoplasms / Urinary Diversion (徳島大学機関リポジトリ) ● Metadata: 116363 (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s11701-021-01256-x (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34081290 ● Search Scopus @ Elsevier (PMID): 34081290 ● Search Scopus @ Elsevier (DOI): 10.1007/s11701-021-01256-x (徳島大学機関リポジトリ: 116363, DOI: 10.1007/s11701-021-01256-x, PubMed: 34081290)
21.	Kyotaro Fukuta, Keito Shiozaki, Saki Kobayashi, Ryoichi Nakanishi, Hirofumi Izaki, Kazuya Kanda, Tohru Inai, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma, Case Reports in Oncology, Vol.15, No.1, 369-375, 2022. (要約) A 72-year-old man visited our hospital due to pollakiuria and lower abdominal pain. Urinary cytology was positive, and cystoscopy revealed diffuse edematous nonpapillary tumor. We performed transurethral biopsy, and clinical stage T3 plasmacytoid variant of urothelial carcinoma (PUC) was diagnosed. Although we planned for radical cystectomy, peritoneal dissemination and lung and pelvic lymph node metastases appeared 3 weeks after the initial visit. We also planned for chemotherapy; however, the metastases rapidly progressed, and he died 7 weeks after the biopsy. PUC is rare and shows an aggressive clinical course and poor prognosis. (徳島大学機関リポジトリ) ● Metadata: 117426 (出版サイトへのリンク) ● Publication site (DOI): 10.1159/000524038 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35529298 ● Search Scopus @ Elsevier (PMID): 35529298 ● Search Scopus @ Elsevier (DOI): 10.1159/000524038 (徳島大学機関リポジトリ: 117426, DOI: 10.1159/000524038, PubMed: 35529298)
22.	Kitahata Kanako, Takayuki Uchida, Taniguchi Runa, Kato Ayano, Kosuke Sugiura, Iori Sakakibara, Oarada Motoko, Tomoya Fukawa, Junsoo Park, Inho Choi and Takeshi Nikawa : Additional effects of simultaneous treatment with C14-Cblin and celastrol on the clinorotation-induced rat L6 myotube atrophy, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 127-134, 2022. (要約) Two novel reagents, N-myristoylated Cbl-b inhibitory peptide (C14-Cblin) and celastrol, a quinone methide triterpene, are reported to be effective in preventing myotube atrophy. The combined effects of C14-Cblin and celastrol on rat L6 myotubes atrophy induced by 3D-clinorotation, a simulated microgravity model, was investigated in the present study. We first examined their effects on expression in atrogenes. Increase in MAFbx1/atrogin-1 and MuRF-1 by 3D-clinorotation was significantly suppressed by treatment with C14-Cblin or celastrol, but there was no additive effect of simultaneous treatment. However, celastrol significantly suppressed the upregulation of Cbl-b and HSP70 by 3D-clinorotation. Whereas 3D-clinorotation decreased the protein level of IRS-1 in L6 myotubes, C14-Cblin and celastrol inhibited the degradation of IRS-1. C14-Cblin and celastrol promoted the phosphorylation of FOXO3a even in microgravity condition. Simultaneous administration of C14-Cblin and celastrol had shown little additive effect in reversing the impairment of IGF-1 signaling by 3D-clinorotation. While 3D-clinorotation-induced marked oxidative stress in L6 myotubes, celastrol suppressed 3D-clinorotation-induced ROS production. Finally, the C14-Cblin and celastrol-treated groups were inhibited decrease in L6 myotube diameter and increased the protein content of slow-twitch MyHC cultured under 3D-clinorotation. The simultaneous treatment of C14-Cblin and celastrol additively prevented 3D-clinorotation-induced myotube atrophy than single treatment. J. Med. Invest. 69 : 127-134, February, 2022. (キーワード) Animals / Atrophy / Humans / Muscle Fibers, Skeletal / Pentacyclic Triterpenes / Rats / Rotation (徳島大学機関リポジトリ) ● Metadata: 116937 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.69.127 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466134 ● Search Scopus @ Elsevier (PMID): 35466134 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.127 (徳島大学機関リポジトリ: 116937, DOI: 10.2152/jmi.69.127, PubMed: 35466134)
23.	Keito Shiozaki, Yasuo Kawanishi, Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Kazuyoshi Izumi, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiroomi Kanayama : Clinical application of virtual imaging guided Robot-assisted partial nephrectomy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 237-243, 2022. (要約) Objectives : To evaluate whether virtual partial nephrectomy images could help surgeons identify vascular and collecting system around tumors during actual surgery. Materials & methods : We retrospectively analyzed 36 patients who underwent robot-assisted partial nephrectomy (RAPN) between 2016 and 2017. Virtual partial nephrectomy images were created from preoperative CT images using computer software, and then analyzed. For analysis, blood vessels and collecting system portions within a 5-mm-thick safety margin around the tumor were examined. During analysis, we predicted whether targeted vasculature around the tumor would require clipping or suturing during surgery, and also whether the collecting system would require opening during resection. Surgical outcomes for virtual partial nephrectomy analyses and actual RAPNs were compared and analyzed for sensitivity and specificity. Results : In 36 cases, 119 arteries and 100 veins were targeted on virtual partial nephrectomy images. Arterial suturing or clipping for hemostasis showed a sensitivity and specificity of 83.3% and 84.5%, respectively. For veins, the sensitivity and specificity were 39.1% and 92.2%, respectively. Collecting system opening prediction sensitivity was 85.7%, and specificity was 65.2%. Conclusion : Virtual partial nephrectomy imaging is useful for RAPN planning, particularly regarding arteries and the collecting system. It is hoped that techniques for visualizing veins will improve. J. Med. Invest. 69 : 237-243, August, 2022. (キーワード) Humans / Kidney Neoplasms / Nephrectomy / Retrospective Studies / Robotic Surgical Procedures / Robotics / Treatment Outcome (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.69.237 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244775 ● Search Scopus @ Elsevier (PMID): 36244775 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.237 (DOI: 10.2152/jmi.69.237, PubMed: 36244775)
24.	Madoka Kohno, ANAYT ULLA, Rina Taniguchi, Akane Ohishi, Kako Hirayama, Yuma Takemura, Shoichiro Takao, Yuki Kanazawa, Yuki Matsumoto, Masafumi Harada, Tomoya Fukawa, Hiro-omi Kanayama, Takayuki Uchida, Toshio Suzuki and Takeshi Nikawa : Daily Dietary Supplementation with Steamed Soybean Improves Muscle Volume and Strength in Healthy People Lacking Exercise., Journal of Nutritional Science and Vitaminology, Vol.68, No.6, 521-526, 2022. (要約) Various dietary protein supplements are used by the elderly and bedridden to maintain their skeletal muscle mass and functions. High-quality proteins act as an anabolic driver and help to improve muscle strength and performance. Previously, we reported that soy protein significantly attenuates denervation-induced loss of muscle mass and myofiber cross sectional area in mice with inhibition of ubiquitination and degradation of IRS-1 in tibialis anterior muscle. It also increased muscle volume and strength in bedridden patients. In the present study, we investigated the effects of dietary soybean supplementation on muscle functions in taxi drivers lacking vigorous physical exercise. We conducted a case-control study on 25 healthy, male taxi drivers between the ages of 36 and 71 y performing minimal physical exercise. They were divided into two dietary groups: the soybean diet group (n=13) who ate daily meals (dinner) supplemented with 50 g of steamed soybean for 30 d and the control diet group (n=12) who received no soybean supplement. Next, we measured the muscle cross-sectional area (CSA) and muscle strength and function in both the groups before and after 30 d of soybean intake. The body weights of both diet groups did not differ significantly over time. However, after 30 d of soybean supplementation, the soybean-fed group developed significantly higher muscle CSA and grip strength compared to the control groups. In conclusion, dietary soybean supplementation improved muscle function in taxi drivers who lacked exercise. (キーワード) Male / Animals / Mice / Soybeans / Case-Control Studies / Muscle, Skeletal / Dietary Supplements / Muscle Strength / Dietary Proteins (出版サイトへのリンク) ● Publication site (DOI): 10.3177/jnsv.68.521 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36596550 ● Search Scopus @ Elsevier (PMID): 36596550 ● Search Scopus @ Elsevier (DOI): 10.3177/jnsv.68.521 (DOI: 10.3177/jnsv.68.521, PubMed: 36596550)
25.	山口邦久, 佐々木雄太郎, 布川朋也, 高橋正幸, 金山博臣 : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.1, No.19, 118-121, 2021年. (キーワード) 腎移植 / リンパ漏 / リンパ管造影 / ジンイショク / リンパロウ / リンパカンゾウエイ (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1523388081028360448 (CiNii: 1523388081028360448)
26.	佐々木雄太郎, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, 大豆本圭, 尾崎啓介, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣, 柏原秀也, 徳永卓哉 : 局所進行直腸癌に対してロボット支援骨盤内臓全摘除術および体腔内回腸導管造設術を施行した2例, 泌尿器科紀要, Vol.68, No.5, 155-159, 2021年. (キーワード) Robot-assisted total pelvic exenteration / Intracorporeal urinary diversion / Intracorporeal ileal conduit (出版サイトへのリンク) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390855656035011840 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_5_155 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840)
27.	佐々木雄太郎, 角陸文哉, 深谷友祐, 山本拓, 大豆本圭, 尾崎啓介, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣 : 膀胱浸潤を来たした局所進行性前立腺癌に対してロボット支援腹腔鏡下膀胱前立腺全摘除術を施行した1例, 泌尿器科紀要, Vol.67, No.4, 163-166, 2021年. (要約) While robot-assisted radical cystoprostatectomy (RARC) for locally advanced prostate cancer (LAPC) may sometimes prove to be excessive treatment, it can significantly reduce the risk of positive surgical margins and lower urinary tract obstruction in some cases. Here, we report a case of LAPC treated with RARC in a patient with right hydronephrosis due to bladder infiltration and left hypoplastic kidney. A 71-year-old man presented with frequent urination in August 2019. Prostate-specific antigen (PSA) level was 8.633 ng/ml, and magnetic resonance imaging led to the suspicion that the prostate cancer extended beyond the prostate capsule without distant metastasis. Prostatic biopsy revealed Gleason score 10 (5+5) adenocarcinoma in 8 out of 8 specimens. We diagnosed left hypoplastic kidney and LAPC with right hydronephrosis due to bladder infiltration. We performed percutaneous right nephrostomy and started neoadjuvant hormone therapy. RARC and intracorporeal ileal conduit were performed in March 2020. The prostate was adherent to the anterior surface of the rectum and was difficult to remove. At present, five months after the surgery, the patient remains free of recurrence and metastasis with PSA level <0.003 ng/ml. RARC for LAPC with bladder infiltration can be an effective therapeutic strategy in some cases. (キーワード) Locally advanced prostate cancer / Bladder Invasion / Robot-assisted radical cystoprostatectomy (出版サイトへのリンク) ● Publication site (DOI): 10.14989/ActaUrolJap_67_4_163 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34107613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85108011497 (DOI: 10.14989/ActaUrolJap_67_4_163, PubMed: 34107613, Elsevier: Scopus)
28.	Yutaro Sasaki, Masayuki Takahashi, Keisuke Ozaki, Kei Daizumoto, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Efficacy of the direct grasping technique using pean forceps under fluoroscopy to replace ureteral stents in women, The Journal of Medical Investigation : JMI, Vol.3.4, No.68, 326-329, 2021. (要約) Purpose : To evaluate the efficacy of the direct grasping technique using pean forceps under fluoroscopic guidance for ureteral stent replacement in women. Methods : Between April 2018 and September 2020, 28 female patients underwent ureteral stent replacements at our facility, and 184 stent replacement procedures were performed. A total of 127 stents were replaced using pean forceps under fluoroscopic guidance (pean forceps group), and 57 stents were replaced using the cystoscope (cystoscopy group). Clinical characteristics and surgical outcomes were compared between the groups. Results : All stents were successfully replaced. There was a statistically significant difference in the procedure time between the two groups (median [interquartile range], pean forceps group : 10.8 [8.2-13.9] minutes vs. cystoscopy group : 15.8 [11.1-20.9] minutes, P < 0.001). There were no intraoperative complications in either group and no difference in the incidence of postoperative complications (pean forceps group : 1.6% vs. cystoscopy group : 1.8%, P = 1.000). Fluoroscopy time was longer in the pean forceps group, although this difference was not statistically significant (pean forceps group : 38.9 [22.6-60.1] seconds vs. cystoscopy group : 33.0 [20.0-48.9] seconds, P = 0.0558). Conclusion : The direct grasping technique using pean forceps under fluoroscopy may be a beneficial alternative to cystoscopy for ureteral stent replacement in women. J. Med. Invest. 68 : 326-329, August, 2021. (キーワード) 女性 (female) / Fluoroscopy / Humans / Stents / Surgical Instruments / Ureter / Ureteral Obstruction (徳島大学機関リポジトリ) ● Metadata: 116511 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.68.326 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759153 ● Search Scopus @ Elsevier (PMID): 34759153 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.326 (徳島大学機関リポジトリ: 116511, DOI: 10.2152/jmi.68.326, PubMed: 34759153)
29.	山本恭代, 布川朋也, 津田恵, 矢野哲弘, 大豆本圭, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, 楠原義人, 山口邦久, 高橋正幸, 金山博臣 : 骨盤臓器脱と膀胱憩室を同時に治療した1例, 泌尿器科紀要, Vol.66, No.8, 269-272, 2020年. (要約) We report a case of bladder diverticulum presumably caused by lower urinary tract dysfunction due to pelvic organ prolapse (POP) simultaneously treated with transurethral coagulation (TUC) of the bladder diverticulum and laparoscopic sacrocolpopexy (LSC). A literature search showed this is the first report of bladder diverticulum and POP surgically treated at the same time. A 71-year-old woman was referred to our hospital for the treatment of cystocele. She had both storage and voiding symptoms. She had a POPQ stage III cystocele and stage I uterine prolapse. Ultrasonography and computed tomographic scan showed a large volume of residual urine along with a bladder diverticulum. Since urodynamic studies revealed a low compliance bladder and obstruction, we opined that the lower urinary tract symptoms were induced by the cystocele. TUC of the bladder diverticulum and LSC were performed at the same time. After the operation, clean intermittent catheterization (CIC) was needed once a day for one month. Gradually, residual urine decreased and CIC became unnecessary. The bladder diverticulum disappeared, and there has been no recurrence of POP. (キーワード) Aged / Diverticulum / 女性 (female) / Humans / Lower Urinary Tract Symptoms / Pelvic Organ Prolapse / Urinary Bladder / Urinary Bladder, Overactive (出版サイトへのリンク) ● Publication site (DOI): 10.14989/ActaUrolJap_66_8_269 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32882124 ● Summary page in Scopus @ Elsevier: 2-s2.0-85090318500 (DOI: 10.14989/ActaUrolJap_66_8_269, PubMed: 32882124, Elsevier: Scopus)
30.	Yoshito Kusuhara, Kei Daizumoto, Kaichi Kawai, Kento Hirayama, Minoru Kowada, Terumichi Shintani, Yayoi Fukuhara, Tsogt-Ochir Dondoo, Keisuke Ozaki, Megumi Tsuda, Tomoya Fukawa, Hiroyoshi Nakatsuji, Yoshimi Bando, Hisanori Uehara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer., Anticancer Research, Vol.39, No.2, 703-711, 2019. (要約) Low TLR4 expression was correlated with tumor progression. (キーワード) Aged / Biomarkers, Tumor / Cell Differentiation / Cell Line, Tumor / Computational Biology / Disease Progression / Female / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Male / Middle Aged / Neoplasm Invasiveness / Oligonucleotide Array Sequence Analysis / Prognosis / RNA, Small Interfering / Toll-Like Receptor 4 / Urinary Bladder Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.21873/anticanres.13166 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30711948 ● Search Scopus @ Elsevier (PMID): 30711948 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13166 (DOI: 10.21873/anticanres.13166, PubMed: 30711948)
31.	Tomoya Fukawa and Hiro-omi Kanayama : Current knowledge of risk factors for testicular germ cell tumors., International Journal of Urology, Vol.25, No.4, 337-344, 2018. (要約) The development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned. (キーワード) 腫瘍学 (oncology) / Testicular tumor (出版サイトへのリンク) ● Publication site (DOI): 10.1111/iju.13519 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29345008 ● Search Scopus @ Elsevier (PMID): 29345008 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.13519 (DOI: 10.1111/iju.13519, PubMed: 29345008)
32.	Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, Masaya Ono, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer, Cancer Research, Vol.78, No.9, 2233-2247, 2018. (要約) The p53 and EGFR pathways are frequently altered in bladder cancer, yet their contributions to its progression remain elusive. Here we report that DEAD box polypeptide 31 (DDX31) plays a critical role in the multistep progression of muscle-invasive bladder cancer (MIBC) through its sequential interactions with mutant p53 (mutp53) and EGFR. In early MIBC cells, nuclear DDX31-bound mutp53/SP1 enhanced mutp53 transcriptional activation, leading to migration and invasion of MIBC. Cytoplasmic DDX31 also bound EGFR and phospho-nucleolin in advanced MIBC, leading to EGFR-Akt signaling activation. High expression of both cytoplasmic DDX31 and p53 proteins correlated with poor prognosis in patients with MIBC, and blocking the DDX31/NCL interaction resulted in downregulation of EGFR/Akt signaling, eliciting an antitumor effect against bladder cancer. These findings reveal that DDX31 cooperates with mutp53 and EGFR to promote progression of MIBC, and inhibition of DDX31/NCL formation may lead to potential treatment strategies for advanced MIBC. DDX31 cooperates with mutp53 and EGFR to promote progression of muscle invasive bladder cancer. . (徳島大学機関リポジトリ) ● Metadata: 111804 (出版サイトへのリンク) ● Publication site (DOI): 10.1158/0008-5472.CAN-17-2528 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29440146 ● Search Scopus @ Elsevier (PMID): 29440146 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-17-2528 (徳島大学機関リポジトリ: 111804, DOI: 10.1158/0008-5472.CAN-17-2528, PubMed: 29440146)
33.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (要約) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (キーワード) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / 男性 (male) / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (徳島大学機関リポジトリ) ● Metadata: 113626 (出版サイトへのリンク) ● Publication site (DOI): 10.21873/invivo.11127 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (徳島大学機関リポジトリ: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
34.	Terumichi Shintani, Yoshito Kusuhara, Kei Daizumoto, Tsogt-Ochir Dondoo, Yasuyo Yamamoto, Hidehisa Mori, Tomoya Fukawa, Hiroyoshi Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells., Urology, Vol.101, 169.e7-169.e13, 2017. (要約) To clarify the invasive mechanisms of muscle-invasive bladder cancer (BCa) would be useful for the determination of appropriate treatment strategies. We previously showed that hepatocyte growth factor (HGF)-MET signaling is correlated with invasiveness of BCa cells. Here, we investigated the effects of the MET inhibitor, cabozantinib (XL184), on BCa cells. We first conducted Western blot analysis to investigate MET expression in BCa cell lines. Next, we examined the effect of cabozantinib on their proliferation and invasive abilities using MTT and Matrigel invasion assays, respectively. Invasion assays were performed using the xCELLigence system. Additionally, to investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles and performed real-time polymerase chain reaction analyses of 5637 cells that were cultivated with or without HGF stimulation, with or without cabozantinib. MET was highly expressed in 4 of 5 BCa cell lines, and 5637 and T24 cells showed especially high protein expression of MET. Cabozantinib suppressed cell proliferation and invasion (cell index; mock, 1.49 vs HGF, 2.26 vs HGF + XL184, 1.47, P < .05). Gene expression profile analysis indicated that matrix metalloproteinase 1 (MMP1) was significantly elevated at the mRNA level with addition of HGF. Moreover, cabozantinib suppressed HGF-induced MMP1 expression in 5637 T24 cells. These data indicate that cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa. (キーワード) Anilides / Blotting, Western / Cell Count / Cell Line, Tumor / Cell Proliferation / Gene Expression Regulation, Neoplastic / Hepatocyte Growth Factor / Humans / Matrix Metalloproteinase 1 / Neoplasm Invasiveness / Protein Array Analysis / Proto-Oncogene Proteins c-met / Pyridines / RNA, Neoplasm / Receptor Protein-Tyrosine Kinases / Reverse Transcriptase Polymerase Chain Reaction / シグナル伝達 (signal transduction) / Urinary Bladder / Urinary Bladder Neoplasms (徳島大学機関リポジトリ) ● Metadata: 110112 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.urology.2016.12.006 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28013036 ● Summary page in Scopus @ Elsevier: 2-s2.0-85009932260 (徳島大学機関リポジトリ: 110112, DOI: 10.1016/j.urology.2016.12.006, PubMed: 28013036, Elsevier: Scopus)
35.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (要約) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (出版サイトへのリンク) ● Publication site (DOI): 10.1159/000439573 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
36.	小居浩之, 大豆本圭, 山本恭代, 香川純一郎, 小森政嗣, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣, 井崎博文 : FDG-PETにて高集積を認めた後腹膜神経鞘腫の1例, 西日本泌尿器科, Vol.77, No.8, 297-301, 2015年. (キーワード) 後腹膜神経鞘腫 / ¹⁸F-FDGPET-CT / retroperitoneal schwannoma (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520853833143993344 ● Summary page in Scopus @ Elsevier: 2-s2.0-84941121427 (CiNii: 1520853833143993344, Elsevier: Scopus)
37.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer., Clinical Genitourinary Cancer, Vol.13, No.4, e337-40, 2015. (キーワード) Aged / Antineoplastic Agents / Bone Neoplasms / Drug Administration Schedule / Fatal Outcome / Humans / Maintenance Chemotherapy / Male / Middle Aged / Prostatic Neoplasms, Castration-Resistant / Taxoids (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.clgc.2015.01.012 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25770768 ● Summary page in Scopus @ Elsevier: 2-s2.0-84936985299 (DOI: 10.1016/j.clgc.2015.01.012, PubMed: 25770768, Elsevier: Scopus)
38.	佐々木雄太郎, 小居浩之, 大山拓郎, 香川純一郎, 小森政嗣, 仙崎智一, 布川朋也, 髙橋久弥, 武村政彦, 山口邦久, 山本恭代, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 多発骨転移をきたした筋層非浸潤性膀胱癌の1例, 泌尿器科紀要, Vol.59, No.10, 669-672, 2013年. (要約) A 66-year-old man with superficial bladder cancer was treated with transurethral resection (TURBT) in October 2011. The pathological diagnosis was urothelial carcinoma (UC), grade 2, T1. A second TURBT was performed one month later. The pathological diagnosis was UC, grade 3, T1. He was treated with intravesical bacillus Calmette-Guerin (BCG) after TURBT. His progress was satisfactory, but a small superficial bladder cancer was found on cystoscopy in August 2012. He was going to be treated with TURBT, but the serum alkaline phosphatase level was abnormally high on preoperative evaluation. Bone scintigraphy showed multiple bone metastases from non-muscle invasive bladder cancer (NMIBC) without local invasion. He was started on combined chemotherapy with 1,000 mg/m2 gemcitabine on days 1, 8 and 15 and 70 mg/m2 cisplatin on day 2 every four weeks. He received denosumab for multiple bone metastases at the same time. Although he subsequently developed severe hypocalcemia, treatment was continued, and he completed four courses of chemotherapy. Bone scintigraphy and contrast-enhanced computed tomography showed reduction of the multiple bone metastases, and alkaline phosphatase decreased to the normal range. It is rare for NMIBC without local invasion to metastasize to other organs. Thus, it is necessary to consider distant metastases in patients with NMIBC. (キーワード) Non-muscle invasive / Bladder cancer / Bone metastasis (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24262709 ● CiNii @ 国立情報学研究所 (CRID): 1050845760708113920 ● Summary page in Scopus @ Elsevier: 2-s2.0-84888314282 (PubMed: 24262709, CiNii: 1050845760708113920, Elsevier: Scopus)
39.	高橋正幸, 小森政嗣, 香川純一郎, 仙崎智一, 布川朋也, 武村政彦, 髙橋久弥, 山本恭代, 山口邦久, 井崎博文, 福森知治, 金山博臣 : 小児低形成腎/機能低下腎に対する腹腔鏡下腎摘除術の臨床的検討, Japanese Journal of Endourology, Vol.26, No.2, 263-269, 2013年. (要約) 当科において小児の低形成腎/機能低下腎に対する鏡視下腎摘除術を再検討した．1993年12月より，低形成腎/機能低下腎の小児10例に対し，鏡視下腎摘除術を施行した．年齢の中央値5.5歳，男1例，女9例．尿管異所開口に伴う低形成腎8例，巨大尿管症，高度VURによる機能低下腎が各1例．手術は，経腹膜的アプローチ5例，後腹膜的アプローチ5例，手術時間中央値は167分．術中合併症はなく，術後合併症は，皮下気腫1例，発熱1例．術後鎮痛剤は，3例は使用なし，7例は術後に坐薬を1∼数回使用．食事開始は中央値で術後1日目，歩行開始日中央値は術後1.5日．術後入院期間中央値は4.5日，術後から退院可能日までの中央値3.0日．小児の低形成腎/機能低下腎に対する鏡視下腎摘除術は，術後の疼痛も少なく，美容的にも良好で，標準的な低侵襲手術である． (キーワード) 小児 / 鏡視下腎摘除術 / 尿管異所開口 (出版サイトへのリンク) ● Publication site (DOI): 10.11302/jsejje.26.263 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205509695360 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.26.263 (DOI: 10.11302/jsejje.26.263, CiNii: 1390001205509695360)
40.	Masayuki Takahashi, Kawabata Rumi, Kawano Akira, Murakami Yoshihide, Sutou Yasushi, Inai Tohru, Akazawa Seiji, Hamao Takumi, Hayashi Hideki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : Substitution of antiandrogens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study, International Journal of Oncology, Vol.43, No.3, 713-720, 2013. (要約) We conducted this study to determine whether substitution with anti-androgen (SOA) and tegafur-uracil (a pro-drug of 5-FU) combination therapy is more effective than SOA alone after relapse from initial hormonal therapy. Patients who were histologically confirmed and relapsed after initial hormonal therapy were included. All patients were randomly allocated into two groups: SOA alone (group A) or SOA combined with tegafur-uracil (group B). The mRNA expression of four enzymes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phospho-ribosyltransferase (OPRT) and thymidine phosphorylase (TP), in prostate cancer cells was analyzed by quantitative reverse-transcription polymerase chain reaction. Fifty-two patients were enrolled in this study. The median age was 77 (range: 47-92) years. The PSA response rate in group B (61.5%) tended to be higher compared to that in group A (34.6%) (p=0.095). Group B (median: 15.9 months) had a significantly longer time to PSA progression (TTP) compared to group A (6.4 months) (p=0.014). In patients with a lower TS expression or a higher OPRT expression, group B demonstrated a higher PSA response rate compared to group A (p=0.019 and p=0.041, respectively). In addition, in the patients with a lower TS expression, group B demonstrated a significantly longer TTP compared to group A (p=0.018). There were no severe adverse events in either treatment group. After relapse from initial hormonal therapy, SOA combined with tegafur-uracil is effective and well tolerated. The TS mRNA expression level may be a predictive factor for this combination therapy. (キーワード) Aged / Aged, 80 and over / Androgen Antagonists / Antineoplastic Combined Chemotherapy Protocols / Dihydrouracil Dehydrogenase (NADP) / Gene Expression Regulation, Neoplastic / Humans / Male / Middle Aged / Orotate Phosphoribosyltransferase / Prostatic Neoplasms, Castration-Resistant / RNA, Messenger / Tegafur / Thymidine Phosphorylase / Thymidylate Synthase / Uracil (出版サイトへのリンク) ● Publication site (DOI): 10.3892/ijo.2013.1997 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23817692 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880578556 (DOI: 10.3892/ijo.2013.1997, PubMed: 23817692, Elsevier: Scopus)
41.	髙橋久弥, 山本恭代, 小居浩之, 大山拓郎, 佐々木雄太郎, 小森政嗣, 香川純一郎, 仙崎智一, 布川朋也, 武村政彦, 山口邦久, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 間質性膀胱炎に対する水圧拡張術の経験, 西日本泌尿器科, Vol.75, No.8, 413-417, 2013年. (キーワード) 間質性膀胱炎 / 水圧拡張術 / interstitial cystitis (IC) hydrodistension (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520290882119498752 ● Summary page in Scopus @ Elsevier: 2-s2.0-84884299458 (CiNii: 1520290882119498752, Elsevier: Scopus)
42.	Kojiro Nagai, Masashi Miyoshi, Takei Kake, Naoshi Fukushima, Motokazu Matsuura, Eriko Shibata, Satoshi Yamada, Kazuhiro Yoshikawa, Hiro-omi Kanayama, Tomoya Fukawa, Kunihisa Yamaguchi, Hirofumi Izaki, Akira Mima, Naoko Abe, Toshikazu Araoka, Taichi Murakami, Fumi Kishi, Seiji Kishi, Tatsuya Tominaga, Tatsumi Moriya, Hideharu Abe and Toshio Doi : Dual Involvement of Growth Arrest-specific Gene 6 in the Early Phase of Human IgA Nephropathy, PLoS ONE, Vol.8, No.6, e66759, 2013. (要約) Gas6 is a growth factor that causes proliferation of mesangial cells in the development of glomerulonephritis. Gas6 can bind to three kinds of receptors; Axl, Dtk, and Mer. However, their expression and functions are not entirely clear in the different glomerular cell types. Meanwhile, representative cell cycle regulatory protein p27 has been reported to be expressed in podocytes in normal glomeruli with decreased expression in proliferating glomeruli, which inversely correlated with mesangial proliferation in human IgA nephropathy (IgAN). The aim of this study is to clarify Gas6 involvement in the progression of IgAN. Expression of Gas6/Axl/Dtk was examined in 31 biopsy proven IgAN cases. We compared the expression levels with histological severity or clinical data. Moreover, we investigated the expression of Gas6 and its receptors in cultured podocytes. In 28 of 31 cases, Gas6 was upregulated mainly in podocytes. In the other 3 cases, Gas6 expression was induced in endothelial and mesangial cells, which was similar to animal nephritis models. Among 28 podocyte type cases, the expression level of Gas6 correlated with the mesangial hypercellularity score of IgAN Oxford classification and urine protein excretion. It also inversely correlated with p27 expression in glomeruli. As for the receptors, Axl was mainly expressed in endothelial and mesangial cells, while Dtk was expressed in podocytes. In vitro, Dtk was expressed in cultured murine podocytes, and the expression of p27 was decreased by Gas6 stimulation. Gas6 was uniquely upregulated in either endothelial/mesangial cells or podocytes in IgAN. The expression pattern can be used as a marker to classify IgAN. Gas6 has a possibility to be involved in not only mesangial proliferation via Axl, but also podocyte injury via Dtk in IgAN. (キーワード) Cells, Cultured / Endothelial Cells / Glomerulonephritis, IGA / Humans / Immunohistochemistry / Intercellular Signaling Peptides and Proteins / Mesangial Cells / Podocytes (出版サイトへのリンク) ● Publication site (DOI): 10.1371/journal.pone.0066759 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23826128 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879474790 (DOI: 10.1371/journal.pone.0066759, PubMed: 23826128, Elsevier: Scopus)
43.	Tomoteru Kishimoto, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Mineralocorticoid receptor expression in human penile corpus cavernosum, The Journal of Medical Investigation : JMI, Vol.60, 21-26, 2013. (要約) Mineralocorticoid receptor (MR) is known to play physiological and pathophysiological roles in the cardiovascular system, and MR activation directly damages these organs. The aim of this study was to evaluate the expression of MR and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the human penile corpus cavernosum. MR and 11β-HSD2 expression was assayed in human penile tissues, and also in human renal tissues as a positive control. Expressions of MR mRNA and 11β-HSD2 mRNA were evaluated using reverse transcription polymerase chain reaction (RT-PCR). MR and 11β-HSD2 were visually identified using immunofluorescence analysis. MR mRNA expression in human penis was confirmed by RT-PCR. On quantitative RT-PCR analysis, 11β-HSD2 mRNA expression was detected at minimal levels in penile tissue. Immunofluorescence analysis revealed positive staining for MR and negative staining for 11β-HSD2 in smooth muscle cells of the corpus cavernosum. This study demonstrated the presence of MR and the absence of 11β-HSD2 in human penile corpus cavernosum. Considering that MR activation causes various organ damages, MR blockade in human penile corpus cavernosum may have therapeutic benefits. Investigations for the penile effects of MR activation have the potential to provide new treatment approaches for erectile dysfunction. (キーワード) 11-beta-Hydroxysteroid Dehydrogenase Type 2 / Adult / Aged / Erectile Dysfunction / Fluorescent Antibody Technique / Humans / Male / Middle Aged / Mineralocorticoid Receptor Antagonists / Penis / RNA, Messenger / Receptors, Mineralocorticoid (徳島大学機関リポジトリ) ● Metadata: 106037 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.60.21 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614907 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876057957 (徳島大学機関リポジトリ: 106037, DOI: 10.2152/jmi.60.21, PubMed: 23614907, Elsevier: Scopus)
44.	髙橋久弥, 津田恵, 大豆本圭, 三宅毅志, 塩﨑啓登, 小森政嗣, 香川純一郎, 仙崎智一, 布川朋也, 武村政彦, 山口邦久, 山本恭代, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : BCG膀胱内注入療法に合併したReiter症候群の経験, 西日本泌尿器科, Vol.76, 10-14, 2013年. (キーワード) Reiter症候群 / BCG膀胱内注入療法 / 膀胱癌 / Reiter's syndrome / intravesical BCG therapy / bladder cancer (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520853832090604416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894647903 (CiNii: 1520853832090604416, Elsevier: Scopus)
45.	Tomoya Fukawa, Masaya Ono, Taisuke Matsuo, Hisanori Uehara, Tsuneharu Miki, Yusuke Nakamura, Hiro-omi Kanayama and Toyomasa Katagiri : DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas, Cancer Research, Vol.72, No.22, 5867-5877, 2012. (要約) Studies of renal cell carcinoma (RCC) have led to the development of new molecular-targeted drugs but its oncogenic origins remain poorly understood. Here, we report the identification and critical roles in renal carcinogenesis for DDX31, a novel nucleolar protein upregulated in the vast majority of human RCC. Immunohistochemical overexpression of DDX31 was an independent prognostic factor for patients with RCC. RNA interference (RNAi)-mediated attenuation of DDX31 in RCC cells significantly suppressed outgrowth, whereas ectopic DDX31 overexpression in human 293 kidney cells drove their proliferation. Endogenous DDX31 interacted and colocalized with nucleophosmin (NPM1) in the nucleoli of RCC cells, and attenuation of DDX31 or NPM1 expression decreased pre-ribosomal RNA biogenesis. Notably, in DDX31-attenuated cells, NPM1 was translocated from nucleoli to the nucleoplasm or cytoplasm where it bound to HDM2. As a result, HDM2 binding to p53 was reduced, causing p53 stablization with concomitant G(1) phase cell-cycle arrest and apoptosis. Taken together, our findings define a mechanism through which control of the DDX31-NPM1 complex is likely to play critical roles in renal carcinogenesis. (キーワード) Animals / COS Cells / Carcinoma, Renal Cell / Cell Nucleolus / DEAD-box RNA Helicases / HEK293 Cells / Humans / 免疫組織化学 (immunohistochemistry) / Kidney Neoplasms / Nuclear Proteins / Prognosis / Proto-Oncogene Proteins c-mdm2 / RNA, Ribosomal / シグナル伝達 (signal transduction) / Transcription, Genetic / Transfection / Tumor Suppressor Protein p53 / Up-Regulation (出版サイトへのリンク) ● Publication site (DOI): 10.1158/0008-5472.CAN-12-1645 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23019224 ● Search Scopus @ Elsevier (PMID): 23019224 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-12-1645 (DOI: 10.1158/0008-5472.CAN-12-1645, PubMed: 23019224)
46.	辻岡卓也, 小森正嗣, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣 : BCG膀胱内注入療法後に発症した結核性精巣上体炎の1例, 泌尿器外科, Vol.25, No.11, 2217-2220, 2012年.
47.	高橋正幸, 瀬戸公介, 辻岡卓也, 冨田諒太郎, 津田恵, 小森正嗣, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 金山博臣 : 進行性腎細胞癌に対する薬物療法いつ，何を，どう使う? 進行性腎癌に対する分子標的薬のsequential therapy, 西日本泌尿器科, Vol.74, No.5, 258-263, 2012年. (キーワード) 腎細胞癌 / 分子標的薬 / sequential therapy (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520572357422341632 ● Summary page in Scopus @ Elsevier: 2-s2.0-84861809136 (CiNii: 1520572357422341632, Elsevier: Scopus)
48.	Hisaya Takahashi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Avirmed Shiirevnyamba, Tomoya Fukawa, Masahiko Takemura, Tomoharu Fukumori and Hiro-omi Kanayama : Up-regulation of Plakophilin-2 and Down-regulation of Plakophilin-3 are Correlated With Invasiveness in Bladder Cancer, Urology, Vol.79, No.1, 240e1-240e8, 2012. (要約) To examine plakophilin proteins (Pkp) and 3 expression levels in bladder cancer, in particular their levels during cellular growth and invasion. Pkp is associated with the binding of cadherin to intermediate filaments of the cytoskeleton. The relative mRNA and protein expression levels of Pkp2 and 3 in bladder cancer cell lines were determined using quantitative real-time polymerase chain reaction and Western blot analyses. The cellular localization of Pkp2 and 3 proteins in bladder cancer cells was also assayed using immunohistochemistry. The proliferation and invasive activities of bladder cancer cells were evaluated using cell growth and in vitro cell invasion assays, and were compared with those of bladder cancer cells treated with Pkp2 and 3 small interfering RNAs. Pkp2 mRNA and protein levels were elevated, and those of Pkp3 were reduced, in bladder cancer cells that are known to exhibit increased proliferation and invasive activity. Pkp2/3 protein expression was predominantly observed in the cytoplasm of invasive bladder cancer cells and tissues. Pkp2 knockdown inhibited, and Pkp3 knockdown enhanced, invasion of bladder cancer cells, but these knockdowns did not alter cell proliferation. We conclude that high Pkp2, and low Pkp3, expression is associated with bladder cancer cell invasion and that neither Pkp2 nor Pkp3 is associated with cell proliferation. We further hypothesize that accumulation of Pkp2 and 3 in the cell cytoplasm, rather than their recruitment to the cell membrane, is related to an increased ability of the tumor to invade and metastasize. (キーワード) Blotting, Western / Cell Line, Tumor / Cell Proliferation / Down-Regulation / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Microscopy, Fluorescence / Neoplasm Invasiveness / Plakophilins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Sensitivity and Specificity / Up-Regulation / Urinary Bladder Neoplasms (徳島大学機関リポジトリ) ● Metadata: 106137 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.urology.2011.08.049 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22119253 ● Search Scopus @ Elsevier (PMID): 22119253 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2011.08.049 (徳島大学機関リポジトリ: 106137, DOI: 10.1016/j.urology.2011.08.049, PubMed: 22119253)
49.	福森知治, 中逵弘能, 古谷俊介, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 生島仁史, 金山博臣 : 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績, Japanese Journal of Endourology, Vol.24, No.1, 131-135, 2011年. (キーワード) 前立腺癌 / 密封小線源療法 / リスク分類 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205509858560 (CiNii: 1390001205509858560)
50.	高橋正幸, 山本洋之, 湯浅明人, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 超高齢者の泌尿器がん治療当科における初診時80歳以上の腎腫瘍患者の臨床的検討, 西日本泌尿器科, Vol.72, No.7, 363-370, 2010年. (要約) 初診時80歳以上の腎腫瘍患者24例(男17例・女7例・中央値81.5歳)の成績を報告した．ECOG performance status(PS)は0:9例，1:7例，2:3例，3:1例，4:3例，不明:1例，臨床病期はstage I:11例，II:2例，III:5例，IV:6例であった．腎摘出術を施行したのは6例で，PSは0:4例，1:1例，2:1例，病期はstage I:4例，II:1例，III:1例であった．非手術の理由は，本人・家族が希望しない，手術適応外，合併症の存在などであった．全生存期間の中央値は25ヵ月で，stage I:44ヵ月，II:10ヵ月，III:9ヵ月，IV:25ヵ月であった．癌特異生存期間の中央値はstage I:44ヵ月，II:10ヵ月，III:15ヵ月，IV:18ヵ月であった．stage I・IIの13例を手術施行5例と非手術8例に分け比較したが，全生存率，癌特異生存率ともに有意差はなかった．また，stage III・IVを治療介入7例と無治療3例に分けて行った比較でも，同様に有意差はなかった． (キーワード) RCC / elderly patients / survival / 腎細胞癌 / 高齢者 / 生存率 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520290883090281344 ● Summary page in Scopus @ Elsevier: 2-s2.0-77955855677 (CiNii: 1520290883090281344, Elsevier: Scopus)

学術論文(紀要・その他):

1.	佐々木雄太郎, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, 大豆本圭, 尾崎啓介, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣, 柏原秀也, 徳永卓哉 : 局所進行直腸癌に対してロボット支援骨盤内臓全摘除術および体腔内回腸導管造設術を施行した2例, 泌尿器科紀要, Vol.68, No.5, 155-159, 2022年. (要約) 症例1は71歳男性で，局所進行直腸癌の診断で化学療法および放射線療法を併用し，8コース終了時にPRであった．その後，直腸癌の皮下穿通による外陰部壊死性筋膜炎を発症し，緊急切開ドレナージ，S状結腸ストーマ造設術および経皮的膀胱瘻造設術を施行し，翌月に根治療法としてロボット支援骨盤内臓全摘術(Ra-TPE)，体腔内回腸導管造設術(ICIC)，創閉鎖術を施行した．病理組織結果はmoderately differentiated tubular adenocarcinoma，ypT3N0，RM0であり，術後31日目に退院した．症例2は61歳男性で，痔瘻癌に対しFOLFOXIRI+Cetuximabを計14コース施行後，FOLFIRI+Panitumumabを計14コース施行し，Ra-TPEとICIC，経会陰的直腸間膜切除術を施行した．病理診断はAdenocarcinoma，ypT4N0，RM0であり，術後36日目に退院した．両症例とも肺転移を認め胸腔鏡下肺部分切除術を施行したが，術後12ヵ月時点でその他の転移や局所再発は認めていない． (キーワード) 腫瘍多剤併用療法骨盤内臓器全摘術生検腺癌(X線診断,病理学,治療) X線CT 直腸腫瘍(X線診断,病理学,治療) 尿路変更術膀胱造瘻術ネオアジュバント療法 Oxaliplatin(治療的利用) TS-1(治療的利用) Bevacizumab(治療的利用) 放射線化学療法結腸造瘻術ロボット手術ヒト中年(45∼64) 高齢者(65∼79) 男 (出版サイトへのリンク) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390855656035011840 ● Summary page in Scopus @ Elsevier: 2-s2.0-85132908756 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840, Elsevier: Scopus)
2.	山口邦久, 佐々木雄太郎, 布川朋也, 高橋正幸 : 腎移植後のリンパ漏にリンパ管造成が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.9, No.1, 118-121, 2021年.
3.	井内俊輔, 森英恭, 大豆本圭, 津田恵, 楠原義人, 香川純一郎, 布川朋也, 山本恭代, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 徳島大学泌尿器科におけるBCG膀胱内注入療法の臨床検討, 泌尿器外科, Vol.28, No.3, 330-331, 2015年.
4.	武村政彦, 井崎博文, 小森政嗣, 仙崎智一, 布川朋也, 山本恭代, 山口邦久, 中逵弘能, 高橋正幸, 福森知治, 金山博臣 : 子宮頸癌副腎転移との識別が困難であった18F-FDG PET/CT陽性副腎皮質線種の1例, 泌尿紀要, Vol.59, 91-95, 2013年.
5.	福森知治, 古谷俊介, 中逵弘能, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 生島仁史, 金山博臣 : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 泌尿器外科, Vol.27, No.8, 1651-1654, 2012年.
6.	岸本大輝, 布川朋也, 武村政彦, 山口邦久, 山本恭代, 井崎博文, 高橋正幸, 福森知治, 金山博臣, 香川征 : 射精障害を契機に発見されたトルコ鞍空洞症を伴う汎下垂体機能低下症の1例, 日本性機能学会雑誌, Vol.26, No.1, 21-26, 2011年. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1572543024868809472 (CiNii: 1572543024868809472)
7.	津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : BCG膀胱内注入療法後に生じたReiter症候群の1例, 西日本泌尿器科, Vol.73, No.10, 559-561, 2011年. (キーワード) *BCGワクチン(治療的利用,毒性・副作用) (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-82055207262 (Elsevier: Scopus)
8.	福森知治, 小泉貴裕, 山本洋之, 湯浅明人, 布川朋也, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 金山博臣 : 効果的効率的な泌尿器腹腔鏡手術医の育成徳島大学における泌尿器腹腔鏡技術認定医の育成に対する試み, 西日本泌尿器科, Vol.72, No.6, 285-288, 2010年. (キーワード) 腹腔鏡手術 / トレーニング / 腎臓摘出術 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1520009408512732416 ● Summary page in Scopus @ Elsevier: 2-s2.0-77954345645 (CiNii: 1520009408512732416, Elsevier: Scopus)
9.	Manabu Sakaki, Tomoharu Fukumori, Tomoya Fukawa, Essam Elsamman, Avirmed Shiirevnyamba, Hiroyoshi Nakatsuji and Hiro-omi Kanayama : Clinical significance of Galectin-3 in clear cell renal cell carcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 152-157, 2010. (要約) Overexpression of galectin-3 in a variety of cancer cell lines has been shown to correlate with tumor progression and metastasis. In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological features of CC-RCC. Expression of galectin-3 in the kidney cancer cell lines Caki-1, Caki-2, A704, ACHN and KPK-1 were evaluated using western blot analysis, while galectin-3 expression in CC-RCC tissues and normal parenchyma were measured by real-time PCR and immunohistochemistry. We found that galectin-3 was overexpressed in the Caki-1, Caki-2, A704, ACHN and KPK-1 cell lines and that the expression level in CC-RCC was also significantly higher than that in renal parenchyma obtained from the same patient samples (p=0.039). Galectin-3 expression in CC-RCC with distant metastasis was also significantly higher than that in CC-RCC without distant metastasis (p=0.045). In conclusion, we revealed that galectin-3 is highly expressed in CC-RCC, especially in CC-RCC with distant metastasis, suggesting that galectin-3 may serve as a novel target molecule for predicting CC-RCC metastasis. (キーワード) Adult / Aged / Aged, 80 and over / Carcinoma, Renal Cell / Cell Line, Tumor / Female / ガレクチン-3 (galectin-3) / Humans / Kidney Neoplasms / Male / Middle Aged / Neoplasm Metastasis / Prognosis (徳島大学機関リポジトリ) ● Metadata: 78648 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.57.152 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299755 ● Search Scopus @ Elsevier (PMID): 20299755 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.152 (徳島大学機関リポジトリ: 78648, DOI: 10.2152/jmi.57.152, PubMed: 20299755)
10.	Hirofumi Izaki, Masayuki Takahashi, Avirmed Shiirevnyamba, Ryuichi Taue, Hiroyuki Furumoto, Yoshimi Bando, Yoshihide Murakami, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 174-177, 2010. (要約) Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare. We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma. The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel. However, the patient developed an isolated right adrenal metastasis 15 months postoperatively. The solitary adrenal metastasis (diameter, 5.7 cm) was removed laparoscopically. The patient has now been in good health without recurrence for 5 years and 7 months after laparoscopic surgery. To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection. (キーワード) Adenocarcinoma / Adrenal Gland Neoplasms / Endometrial Neoplasms / Female / Humans / Laparoscopy / Middle Aged / Survivors / Tomography, X-Ray Computed (徳島大学機関リポジトリ) ● Metadata: 77529 (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.57.174 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299759 ● Search Scopus @ Elsevier (PMID): 20299759 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.174 (徳島大学機関リポジトリ: 77529, DOI: 10.2152/jmi.57.174, PubMed: 20299759)
11.	Takahiro Koizumi, Hiroyoshi Nakatsuji, Tomoya Fukawa, Shiirevnyamba Avirmed, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The role of actinin-4 in bladder cancer invasion., Urology, Vol.75, No.2, 357-364, 2009. (要約) To examine actinin-4 expression levels in bladder cancer, in particular its levels during cellular growth and invasion. Actinin-4 is an actin-binding protein that is associated with cell motility and cancer metastasis. (キーワード) Actinin / Cell Proliferation / Humans / Neoplasm Invasiveness / RNA, Messenger / Tumor Cells, Cultured / Urinary Bladder Neoplasms (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.urology.2009.09.037 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19969329 ● Search Scopus @ Elsevier (PMID): 19969329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2009.09.037 (DOI: 10.1016/j.urology.2009.09.037, PubMed: 19969329)

総説・解説:

1.	高橋正幸, 布川朋也, 金山博臣 : 【新腎・泌尿器癌(上)-基礎・臨床研究の進歩-】腎癌腎癌の分子生物学と発癌機序遺伝子異常, 日本臨牀, Vol.75, No.6, 39-46, 2017年8月.

国際会議:

1.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Examination of Mid-Urethral Sling (MUS) for elderly patients over 75 years old, Athens, Oct. 2019.
2.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression to predict the resistance to VEGFR-TKIs and induce PD-L1 expression in advanced clear cell renal cell carcinoma, 2019 ASCO Genitourinary Cancers Symposium, Feb. 2019.
3.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Yoshihiro Tsuruo, Kei Daizumoto and Hidehisa Mori : Usefulness of Fresh Frozen Cadaver and Animal Models for Surgical Training in Laparoscopic Sacrocolpopexy, The 36th World Congress of Endourology, Paris, Sep. 2018.
4.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 113th American Urological Association Annual meeting, May 2018.
5.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : What is an appropriate definition of IPSS resolution that correlates closely with QOL recovery after prostate brachytherapy?, The Journal of Urology, Vol.199, No.4, e274, San Francisco, May 2018. (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.juro.2018.02.718 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1016/j.juro.2018.02.718 (DOI: 10.1016/j.juro.2018.02.718)
6.	Toyomasa Katagiri, Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Ono Masaya and Hiro-omi Kanayama : DDX31 cooperates with mutant p53 and EGFR to promote the multistep progression of invasive bladder cancer, American Association For Cancer Research ANNUAL MEETING 2018, Chicago, Apr. 2018.
7.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Masayuki Takahashi : Long-term Administration of Mirabegron in the Treatment of Overactive Bladder, 37th Congress of the Societe Internationale d'Urologie, Lisbon, Oct. 2017.
8.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Safety and efficacy of low-dose-rate brachytherapy for localized prostate cancer in elderly patients, Lisbon, Oct. 2017.
9.	T Shintani, K Daizumoto, Tomoya Fukawa, H Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy, 2017 European association of Urology, London, Mar. 2017.
10.	Tomoharu Fukumori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling., 2017 European association of Urology, London, Mar. 2017.
11.	Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of insulin receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma, 2017 Genitourinary Cancers Symposium, Feb. 2017.
12.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Clinical characteristics differ in ulcerative and non-ulcerative subtypes of interstitial cystitis/ bladder pain syndrome, International Continence Society, Tokyo, Sep. 2016.
13.	Terumichi Shintani, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low expression of Toll like receptor 4 is associated with squamous differentiation in bladder cancer., The American Urological Association, Inc. 111th Annual Meeting, May 2016.
14.	Tomoharu Fukumori, Dondoo Tsogt-Ochir, K Daizumoto, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is a therapeutic target for castration-resistant prostate cancer., The American Urological Association, Inc. 110th Annual Meeting, New Orleans, May 2015.
15.	Toyomasa Katagiri, Tomoya Fukawa, Taisuke Matsuo and Hiro-omi Kanayama : DDX31 regulates p53 tumor suppressive activity in renal cell carcinomas, Amerian Association for Cancer Research (AACR) Annal Meeting 2013, Washington, D.C., Apr. 2013.
16.	Masayuki Takahashi, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : THE LOW TRANS-SCROTAL ORCHIDOPEXY FOR UNDESCENDED TESTES, The 32nd Congress of the Société Internationale dUrologie, Oct. 2012.
17.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
18.	Tomokazu Senzaki, Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Predictive factors for urinary morbidity after I-125 prostate brachytherapy, 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
19.	T Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, 2012.
20.	Tomoya Fukawa, Ono Masaya, Hisanori Uehara, Taisuke Matsuo, Nakamura Yusuke, Hiro-omi Kanayama and Toyomasa Katagiri : Identification and characterization of RCCDH as a novel molecular target for clear renal cell carcinoma., 70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
21.	Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : A multi-center randomized Phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT®) for prostate cancer with relapse after initial hormonal therapy, 2011 Annual Meeting of American Society of Clinical Oncology, Jun. 2011.

国内講演発表:

1.	鎌倉ほのか, 上住円, 黒澤珠希, 布川朋也, 二川健, 上住聡芳 : ヒト筋幹細胞を用いた筋肥大作用を有する天然由来生理活性生物の同定, 第45回日本分子生物学会年会, 2022年12月.
2.	田中優佳子, 小松里奈, 平田修弥, 布川朋也, 二川健 : がん由来エクソソーム内 micro RNA によるミトコンドリア呼吸鎖複合体制御と筋萎縮発症機序の解明, 第55回日本栄養・食糧学会中国・四国支部大会, 2022年10月.
3.	高橋正幸, 大豆本圭, 福田喬太郎, 安宅祐一朗, 泉和良, 楠原義人, 布川朋也, 金山博臣 : 進行性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の検討: 多施設共同後ろ向き研究, 日本泌尿器腫瘍学会第8回, 2022年10月.
4.	加藤廉平, 前川滋克, 加藤陽一郎, 兼平貢, 高田亮, 松下洋輔, 吉丸哲郎, 布川朋也, 片桐豊雅, 小原航 : 3 次元培養下における新規の癌特異分子PRELID2 の分子機能の解明, 第81回日本癌学会学術総会, 2022年10月.
5.	山本恭代, 津田恵, 大豆本圭, 佐々木雄太郎, 上野恵輝, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 女性神経因性膀胱患者に対するボツリヌス毒素膀胱壁内注入療法の経験, 日本女性骨盤底医学会, 2022年7月. (キーワード) 女性 (female) / 神経因性膀胱 / ボツリヌス毒素膀胱壁内注入療法
6.	堀克仁, 佐々木雄太郎, 角陸文哉, 塩崎啓登, 大豆本圭, 冨田諒太郎, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山口邦久, 山本恭代, 高橋正幸, 金山博臣 : 当院での未固定遺体を用いた内シャント造設術トレーニングの試み ∼生体との違いについて∼, 日本泌尿器科学会四国地方会, 2022年7月.
7.	佐々木雄太郎, 堀克仁, 角陸文哉, 大豆本圭, 上野恵輝, 冨田諒太郎, 津田恵, 楠原義人, 布川朋也, 山口邦久, 山本恭代, 高橋正幸, 金山博臣 : 多診療科で行うロボット支援手術 ∼後方骨盤内臓全摘除術の1例∼, 日本泌尿器科学会四国地方会, 2022年7月.
8.	高田実穂, 榊原伊織, 岸田昂大, 福島拓, 新垣翼, 内田貴之, 布川朋也, 二川健 : 骨格筋におけるAconitase2の機能解明, 第76回日本栄養・食糧学会大会, 2022年6月.
9.	山崎穂, 松木大揮, 中野亘, 杉浦宏祐, 布川朋也, 内田貴之, 榊原伊織, 二川健 : 廃用性筋萎縮におけるアコニターゼ活性の低下とその栄養学的保護, 第76回日本栄養・食糧学会大会, 2022年6月.
10.	山本恭代, 津田恵, 安宅真利花, 大豆本圭, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 当院における難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.35, No.1, 144, 2022年6月. (キーワード) 難治性過活動膀胱 / ボツリヌス毒素膀胱壁内注入療法
11.	佐々木雄太郎, 橋本啓佑, 塩﨑啓登, 楠原義人, 布川朋也, 山口邦久, 山本恭代, 井崎博文, 高橋正幸, 金山博臣 : 女性のRARCにおける膣再建の新たな手法 ∼Benz closure technique∼, 泌尿器科再建再生研究会, 2022年6月.
12.	橋本啓佑, 佐々木雄太郎, 安宅真利花, 多田航生, 中西亮太, 吉岡拓哉, 大豆本圭, 尾崎啓介, 上野恵輝, 津田恵, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣 : ロボット支援体腔内回腸導管造設術においてストマ造設を円滑に行うための工夫, 日本ロボット外科学会学術集会, 2022年2月.
13.	佐々木雄太郎, 福田喬太郎, 大豆本圭, 塩崎啓登, 楠原義人, 布川朋也, 中西良一, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 神田和哉, 金山博臣 : 高齢患者(≧75歳)のロボット支援膀胱全摘除術における体腔内回腸導管造設術と尿管皮膚瘻造設術の比較, 日本泌尿器科学会総会, 2021年12月.
14.	山本恭代, 津田恵, 大豆本圭, 佐々木雄太郎, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 当院における外来排尿自立指導の臨床的検討, 日本泌尿器科學會雜誌, 2021年12月.
15.	佐々木雄太郎, 大豆本圭, 塩崎啓登, 布川朋也, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 神田和哉, 金山博臣 : 「アシステントガイド」の開発体腔内回腸導管造設時の尿管ステント留置を円滑に, 日本泌尿器内視鏡学会総会, 2021年11月.
16.	山本恭代, 津田恵, 大豆本圭, 佐々木雄太郎, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 憩室口が遠位に存在する尿道憩室摘除術における工夫, 西日本泌尿器科, Vol.83, 2021年11月.
17.	山本恭代, 大豆本圭, 佐々木雄太郎, 津田恵, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 夜間頻尿に対するデスモプレシンの使用経験, 日本排尿機能学会誌, Vol.32, No.1, 2021年9月.
18.	山本恭代, 津田恵, 大豆本圭, 佐々木雄太郎, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 骨盤臓器脱に対し膣閉鎖術を行った症例の検討, 日本女性骨盤底医学会, 2021年7月.
19.	山本恭代, 津田恵, 大豆本圭, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の初期治療経験, 日本老年泌尿器科学会誌, Vol.34, No.1, 109, 2021年5月.
20.	高橋正幸, 楠原義人, 佐々木雄太郎, 大豆本圭, 尾﨑啓介, 上野恵輝, 津田恵, 布川朋也, 山本恭代, 山口邦久, 金山博臣 : ロボット支援下腎盂形成術-温故創新成人水腎症に対するロボット支援腎盂形成術の初期経験, 第33回日本内視鏡外科学会総会, 2021年3月.
21.	山本恭代, 布川朋也, 楠原義人, 山口邦久, 高橋正幸, 金山博臣 : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前の下部尿路症状の変化, 第33回日本内視鏡外科学会総会, 2021年3月.
22.	山口邦久, 金山博臣, 高橋正幸, 布川朋也, 楠原義人 : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会, 2021年2月.
23.	高橋正幸, 矢野哲弘, 大豆本圭, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, 津田恵, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 金山博臣 : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第108回日本泌尿器科学会総会, 2020年12月.
24.	山本恭代, 布川朋也, 津田恵, 大豆本圭, 楠原義人, 山口邦久, 高橋正幸, 金山博臣 : 腹腔鏡下仙骨腟固定術前後で比較した下部尿路機能症状とQOLの変化, 第108回日本泌尿器科学会総会, 2020年12月.
25.	山本恭代, 布川朋也, 津田恵, 大豆本圭, 楠原義人, 山口邦久, 高橋正幸, 金山博臣 : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前後での下部尿路症状の変化, 第82回西日本泌尿器科学会総会, 2020年11月.
26.	山本恭代, 津田恵, 大豆本圭, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : TOT手術時のヘガールを用いたテープ調整の有用性, 第27回日本排尿機能学会, 2020年10月.
27.	高橋正幸, 大豆本圭, 布川朋也, 金山博臣 : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
28.	大豆本圭, 福原弥生, 布川朋也, 片桐豊雅, 上原久典, 高橋正幸, 金山博臣 : 尿路上皮癌に対するDDX31/NCL相互作用阻害による抗腫瘍効果の検討, 第79回日本癌学会学術総会, 2020年10月.
29.	尾崎啓介, 山口邦久, 金山博臣, 高橋正幸, 布川朋也 : -, 日本透析医学会雑誌, Vol.53, 813, 2020年10月.
30.	津田恵, 山本恭代, 大豆本圭, 楠原義人, 布川朋也, 山口邦久, 高橋正幸, 金山博臣 : 泌尿器科疾患以外の患者に対する排尿ケアチーム介入の臨床的検討, 第33回日本老年泌尿器科学会総会, 2020年9月.
31.	高橋正幸, 大豆本圭, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, 津田恵, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 金山博臣 : 転移性腎細胞癌に対しニボルマブ・イピリムマブ併用療法を施行した4例の症例報告, 2019年10月.
32.	加藤廉平, 布川朋也, 松下洋輔, 吉丸哲郎, 尾野雅哉, 大豆本圭, 加藤陽一郎, 小原航, 片桐豊雅 : 腎癌の癌化におけるPRELID2によるミトコンドリアROS制御機構の解明, 第78回日本癌学会学術総会, 2019年9月.
33.	山本恭代, 布川朋也, 大豆本圭, 津田恵, 楠原義人, 森英恭, 山口邦久, 高橋正幸, 金山博臣 : RARPにおける術前残尿量と術後尿禁制の関連, 第26回日本排尿機能学会, 2019年9月.
34.	山本恭代, 布川朋也, 津田恵, 大豆本圭, 楠原義人, 森英恭, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 骨盤臓器脱と膀胱憩室を同時に治療した1例, 第21回女性骨盤底医学会, 2019年7月.
35.	高橋正幸, 大豆本圭, 尾﨑啓介, 津田恵, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : 高齢腎癌患者に対する根治的腎摘除術/腎部分切除術の臨床的検討, 第50回腎癌研究会記念大会, 2019年7月.
36.	山本恭代, 大豆本圭, 楠原義人, 津田恵, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 排尿ケアチームが複数回介入した症例の検討, 日本泌尿器科學會雜誌, 2019年4月.
37.	高橋正幸, 西山美月, 福田喬太郎, 大豆本圭, 尾﨑啓介, 津田恵, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期治療経験, 第107回日本泌尿器科学会総会, 2019年4月.
38.	尾崎啓介, 山口邦久, 金山博臣, 高橋正幸, 布川朋也 : ドナー腎採取術における画像解析システム使用の初期経験, 日本臨床腎移植学会抄録集, 249, 2019年2月.
39.	山本恭代, 楠原義人, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣, 鶴尾吉宏 : 腹腔鏡下仙骨膣固定術(LSC: Laparoscopic Sacrocollpopexy)導入にむけたトレーニング, 第31回日本内視鏡外科学会, 2018年12月.
40.	Masayuki Takahashi, Kei Daizumoto, Ozaki Keisuke, Tsuda Megumi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Clinicopathological study of the elderly patients with renal cell carcinoma who underwent radical/partial nephrectomy, 第56回日本癌治療学会学術集会, Oct. 2018.
41.	高橋正幸, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した小児の1症例, 第24回腹膜透析医学会学術集会・総会, 2018年10月.
42.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Minoru Kowada, Yoshimi Bando, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression in vascular endothelial cells of clear cell renal cell carcinoma, 第77回日本癌学会学術集会, Sep. 2018.
43.	加藤廉平, 布川朋也, 吉丸哲郎, 松下洋輔, 尾野雅哉, 大豆本圭, 加藤陽一郎, 小原航, 片桐豊雅 : 腎癌の癌化におけるミトコンドリアPRELID2の重要な役割, 第77回日本癌学会学術総会, 2018年9月.
44.	大豆本圭, 吉丸哲郎, 松下洋輔, 布川朋也, 上原久典, 尾野雅哉, 小松正人, 金山博臣, 片桐豊雅 : 膀胱癌進展機構おけるDDX31の重要な機能「 TP53ステータスに着目して」, 第77回日本癌学会学術総会, 2018年9月.
45.	山口邦久, 金山博臣, 高橋正幸, 山本恭代, 布川朋也 : タクロリムスの血中濃度上昇に術後疼痛に対するフェンタニルの影響が示唆された3例, 移植, Vol.53, 479, 2018年9月.
46.	山本恭代, 大豆本圭, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣, 鶴尾吉宏 : 腹腔鏡下仙骨膣固定術導入にむけたトレーニング, 第20回日本女性骨盤底医学会, 2018年7月.
47.	高橋正幸, 大豆本圭, 尾﨑啓介, 津田恵, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : ニボルマブ投与中にhyper-progressionが疑われた淡明細胞型腎細胞癌の1例, 第49回腎癌研究会, 2018年7月.
48.	高橋正幸, 尾﨑啓介, 楠原義人, 福田喬太郎, 西山美月, 大豆本圭, 津田恵, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : 高齢の腎癌患者に対する手術, 第31回日本老年泌尿器科学会, 2018年5月.
49.	山本恭代, 大豆本圭, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : TOT術後の過活動膀胱(OAB)治療に関する検討, 第106回日本泌尿器科学会総会, 2018年4月.
50.	森英恭, 福森知治, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣 : IPSS resolution, 2018年4月.
51.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 第106回日本泌尿器科学会総会, Apr. 2018.
52.	大豆本圭, 高橋正幸, 宮崎太志, 福原弥生, 楠原義人, 布川朋也, 福森知治, 金山博臣 : 淡明細胞型腎細胞癌・周囲血管におけるインスリンレセプターの発現とVEGFR阻害薬の治療効果との関連性, 第27回泌尿器科分子細胞研究会, 2018年2月.
53.	高橋正幸, 大豆本圭, 尾崎啓介, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : 新規導入施設における気膀胱下Cohen法の問題点と工夫, 第31回日本泌尿器内視鏡学会総会, 2017年11月.
54.	高橋正幸, 大豆本圭, 尾崎啓介, 楠原義人, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : アキシチニブ抵抗性バイオマーカーとしての腎癌組織中インスリンレセプター発現, 第55回日本癌治療学会学術集会, 2017年10月.
55.	福森知治, 森英恭, 川中崇, 久保亜貴子, 古谷俊介, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 生島仁史, 金山博臣 : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, 2017年10月.
56.	大豆本圭, 吉丸哲郎, 布川朋也, 上原久典, 尾野雅哉, 小松正人, 金山博臣, 片桐豊雅 : 筋層浸潤性膀胱癌の多段階進展機構におけるDDX31, Mutant p53, EGFR Axisの役割解明, 第76回日本癌学会学術総会, 2017年9月.
57.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : TOT術後の過活動膀胱(OAB)治療に関する検討, 第24回日本排尿機能学会, 2017年9月.
58.	加藤廉平, 布川朋也, 吉丸哲郎, 松下洋輔, 尾野雅哉, 小原航, 片桐豊雅 : 腎癌の癌化におけるPRELID2の重要な役割, 第76回日本癌学会学術総会, 2017年9月.
59.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 排尿障害から診断を得た多系統萎縮症症例, 日本泌尿器科學會雜誌, 2017年4月.
60.	大豆本圭, 安宅祐一朗, 小藤千鶴, 小和田実, 楠原義人, 森英恭, 新谷晃理, 布川朋也, 山本恭代, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : ロボット支援前立腺全摘術後の尿失禁と内閉鎖筋体積の関連性の検討, 第105回日本泌尿器科学会総会, 2017年4月.
61.	高橋正幸, 安宅祐一郎, 宇都宮聖也, 大豆本圭, 津田恵, 楠原義人, 森英恭, 新谷晃理, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : アキシチニブ投与患者における腎癌組織中のインスリンレセプター発現のバイオマーカーとしての意義, 第105回日本泌尿器科学会総会, 2017年4月.
62.	福森知治, 布川朋也, 楠原義人, 森英恭, 山口邦久, 山本恭代, 高橋正幸, 金山博臣 : The mechanism of tumor progression in prostate cancer by galectin-3 based on the gene profile, 第105回日本泌尿器科学会総会, 2017年4月.
63.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 地方での泌尿器科医療の魅力を上げるには?四国内でのsubspecialty獲得への大学を超えた連携の提言, 第100回四国地方会, Vol.79, No.6, 202, 2017年1月.
64.	山本恭代, 楠原義人, 布川朋也, 森英恭, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 麻酔下膀胱水圧拡張術を施行した間質性膀胱炎の検討, 第16回間質性膀胱炎研究会, 2017年1月.
65.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 当院で加療した高齢者陰唇癒着症の検討, 第23回日本排尿機能学会, 2016年12月.
66.	山本恭代, 楠原義人, 森英恭, 布川朋也, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : TOT手術後に再手術を施行した3症例, 第68回西日本泌尿器科学会総会, 2016年11月.
67.	福森知治, 楠原義人, 森英恭, 新谷晃理, 布川朋也, 山口邦久, 山本恭代, 高橋正幸, 福森知治 : ロボット支援手術でのシステムトラブルの検討, 第30回日本泌尿器内視鏡学会, 2016年11月.
68.	福森知治, 森英恭, 楠原義人, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣 : 高リスク限局性前立腺癌に対するI-125 密封小線源療法の治療成績, 第54回癌治療学会学術集会, 2016年10月.
69.	高橋正幸, 大豆本圭, 楠原義人, 布川朋也, 福森知治, 金山博臣 : 腎がん分子標的治療の解析進行性腎細胞癌におけるアキシチニブの有効性とインスリンレセプター発現の関連性, 第54回日本癌治療学会学術集会, 2016年10月.
70.	福森知治, 楠原義人, 森英恭, 布川朋也, 新谷晃理, 山口邦久, 山本恭代, 高橋正幸, 金山博臣 : 去勢抵抗性前立腺癌患者に対する新規薬剤(アビラテロン，エンザルタミド)の初期使用経験, 第104回日本泌尿器科学会総会, 2016年4月.
71.	福森知治, 布川朋也, 大豆本圭, 津田恵, 井内俊輔, 楠原義人, 森英恭, 香川純一郎, 小森政嗣, 山口邦久, 山本恭代, 高橋正幸, 金山博臣 : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会総会, 2016年4月.
72.	福森知治, 森英恭, 赤沢早紀, 大豆本圭, 津田恵, 楠原義人, 新谷晃理, 香川純一郎, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 金山博臣 : 前立腺癌密封小線源療法後のPSA再発予測因子の検討, 第67回西日本泌尿器科学会総会, 2015年11月.
73.	高橋正幸, 赤澤早紀, 大豆本圭, 津田恵, 楠原義人, 森英恭, 新谷晃理, 香川純一郎, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : 当科における進行性腎細胞癌に対するアキシチニブの治療成績, 第53回日本癌治療学会学術総会, 2015年10月.
74.	福森知治, 森英恭, 川中崇, 久保亜貴子, 古谷俊介, 大豆本圭, 津田恵, 楠原義人, 香川純一郎, 布川朋也, 山本恭代, 山口邦久, 高橋正幸, 生島仁史, 金山博臣 : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, 2015年10月.
75.	大豆本圭, 小松正人, 木村竜一朗, 吉丸哲郎, 上原久典, 尾野雅哉, 布川朋也, 金山博臣, 片桐豊雅 : P53変異型膀胱癌におけるDEAD box polypeptide31(DDX31)の機能解明, 第74回日本癌学会学術総会, 2015年10月.
76.	大豆本圭, 小松正人, 吉丸哲郎, 上原久典, 布川朋也, 金山博臣, 片桐豊雅 : 核小体がんタンパク質BCRG1は膀胱癌の進行に関連している, 第73回日本癌学会学術総会, 2014年9月.
77.	高橋正幸, 大豆本圭, 小森政嗣, 香川純一郎, 布川朋也, 山本恭代, 山口邦久, 福森知治, 金山博臣 : ドセタキセル70サイクル以上の投与により長期生存が得られた進行性前立腺癌の2例, 第52回日本癌治療学会学術集会, 2014年8月.
78.	大豆本圭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : 両側腎腫瘍症例を発端者としたBirt-Hogg-Dube症候群の一家系, 日本泌尿器科総会, 2014年4月.
79.	高橋正幸, 小森政嗣, 香川純一郎, 仙崎智一, 布川朋也, 武村政彦, 髙橋久弥, 山本恭代, 山口邦久, 井崎博文, 福森知治, 金山博臣 : 分子標的薬投与中に腸管穿孔をおこした有転移腎癌の2例, 第51回日本癌治療学会学術集会, 2013年10月.
80.	山本恭代, 福森知治, 仙崎智一, 布川朋也, 武村政彦, 髙橋久弥, 山口邦久, 井崎博文, 高橋正幸, 金山博臣 : 第25回日本老年泌尿器科学会市民公開講座「おしっこの悩みに答えます∼出ない・漏れる・溜まらない∼」のアンケート結果, 日本老年泌尿器科学会誌, Vol.26, No.1, 88, 2013年5月.
81.	福森知治, 中逵弘能, 仙崎智一, 小森政嗣, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 金山博臣 : 高齢(75歳以上)前立腺癌の診断および治療戦略を考える∼放射線治療の適応と照射方法∼, 第26回日本老年泌尿器科学会, 2013年5月.
82.	福森知治, 香川純一郎, 小森政嗣, 仙崎智一, 布川朋也, 武村政彦, 髙橋久弥, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 金山博臣 : 前立腺肥大症に対するデュタステリド投与1年の臨床的検討∼早期の治療効果について∼, 日本泌尿器科学会総会, 2013年4月.
83.	高橋正幸, 小森正嗣, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 福森知治, 金山博臣 : 小児低形成腎/無機能腎に対する腹腔鏡下腎摘除術の検討, 日本泌尿器内視鏡学会, 2012年11月.
84.	福森知治, 仙崎智一, 小森正嗣, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 金山博臣 : Efficacy and safety of dose escalation in I-125 prostate, 第26回日本泌尿器内視鏡学会総会, 2012年11月.
85.	布川朋也, 尾野雅哉, 松尾泰佑, 上原久典, 中村祐輔, 金山博臣, 片桐豊雅 : 腎細胞癌における新規核小体分子RCCDHによるp53制御機構の解明, 第71回日本癌学会学術総会, 2012年9月.
86.	中逵弘能, アビルメードシーレンヤンバ, 布川朋也, 高橋正幸, 福森知治, 高橋正幸, 金山博臣 : 膀胱癌浸潤におけるPlakophilinの関与, 日本癌学会総会, 2012年9月.
87.	山口邦久, 津田恵, 布川朋也, 武村政彦, 山本恭代, 中逵弘能, 井崎博文, 高橋正幸, 福森知治, 金山博臣, 李悦子, 菅政治, 岡本賢二郎 : 徳島大学における生体腎移植初回例の報告, 移植, Vol.46, No.6, 696, 2012年8月. (キーワード) *腎臓移植
88.	山口邦久, 仙崎智一, 布川朋也, 井崎博文, 金山博臣 : 徳島県における献腎摘出の現状, 2012年6月.
89.	山本恭代, 福森知治, 布川朋也, 武村政彦, 山口邦久, 中逵弘能, 井崎博文, 高橋正幸, 金山博臣 : 高齢者に対する尿失禁手術(TOT手術)の臨床的検討, 日本老年泌尿器科学会, 2012年6月.
90.	高橋正幸, 瀬戸公介, 津田恵, 仙崎智一, 小森政嗣, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 金山博臣 : 低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本泌尿器科学会総会, 2012年4月.
91.	福森知治, 中逵弘能, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 金山博臣 : 前立腺癌密封小線源療法後の排尿障害予測因子の検討, 第100回日本泌尿器科学会総会, 2012年4月.
92.	福森知治, 古谷俊介, 中逵弘能, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 生島仁史, 金山博臣 : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 第27回前立腺シンポジウム, 2011年12月.
93.	津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : MIBG療法を施行した悪性褐色細胞腫の1例, 西日本泌尿器科, Vol.73, No.9, 503, 2011年11月. (キーワード) *褐色細胞腫(薬物療法,外科的療法)
94.	高橋正幸, 辻岡卓也, 中島英, 津田恵, 仙崎智一, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 金山博臣 : 進行性腎細胞癌に対する薬物療法いつ，何を，どう使う? 進行性腎癌に対する分子標的薬のsequential therapy, 西日本泌尿器科, Vol.73, 86, 2011年11月. (キーワード) *腎細胞癌(薬物療法)
95.	辻岡卓也, 上野恵輝, 武村政彦, 津田恵, 布川朋也, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣, 西谷真明 : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, 西日本泌尿器科, Vol.73, 127, 2011年11月. (キーワード) *Carboplatin(治療的利用)
96.	武村政彦, 中島英, 富田諒太郎, 津田恵, 布川朋也, 山口邦久, 山本恭代, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣, 三浦浩康 : 不完全重複腎盂尿管に合併した上部尿路結石に対してf-TULを施行した2例, 西日本泌尿器科, Vol.73, 143, 2011年11月. (キーワード) *砕石術
97.	井崎博文, 武村政彦, 高橋正幸, 中辻弘能, 山本恭代, 山口邦久, 布川朋也, 津田恵, 岸本大輝, 上野恵輝, 福森知治, 金山博臣, 三浦浩康 : 徳島大学におけるf-TULの試み導入期に注意したいこと, 西日本泌尿器科, Vol.73, 143, 2011年11月. (キーワード) 病的狭窄(治療)
98.	福森知治, 中逵弘能, 古谷俊介, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 井崎博文, 高橋正幸, 生島仁史, 金山博臣 : 前立腺密封小線源療法前のcombined androgen blockade(CAB)療法の臨床的検討, 日本癌治療学会誌, Vol.46, No.2, 677, 2011年10月. (キーワード) *Androgen Antagonists(治療的利用)
99.	高橋正幸, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 金山博臣 : 当科における進行性/転移性腎腫瘍患者に対するエべロリムスの使用経験, 第49回日本癌治療学会学術集会, 2011年10月.
100.	中島英, 上野恵輝, 武村政彦, 津田恵, 布川朋也, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣, 西谷真明 : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, 日本泌尿器科学会四国地方会, 2011年7月.
101.	冨田諒太郎, 山口邦久, 上野恵輝, 中島英, 瀬戸公介, 辻岡卓也, 津田恵, 布川朋也, 山本恭代, 中逵弘能, 岸本大輝, 武村政彦, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 肉眼的血尿から貧血をきたした悪性黒色腫の膀胱転移に対するTURの経験, 日本泌尿器科学会四国地方会, 2011年7月.
102.	布川朋也, 松尾泰佑, 中村祐輔, 金山博臣, 片桐豊雅 : 腎細胞癌新規分子標的遺伝子RCCDPの同定およびその機能解析, 第15回日本がん分子標的治療学会, 2011年6月.
103.	アビルメドシーレンヤンバ, 中逵弘能, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : Participation of N-caderin in bladder cancer, 日本泌尿器科学会総会, 2011年4月.
104.	武村政彦, 瀬戸公介, 辻岡拓也, 津田恵, 布川朋也, 山口邦久, 中逵弘能, 山本恭代, 井崎博文, 福森知治, 高橋正幸, 金山博臣 : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 日本泌尿器科學會雜誌, Vol.103, No.2, 369, 2011年4月. (キーワード) *血液透析
105.	福森知治, 中逵弘能, 津田恵, 武村政彦, 布川朋也, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 金山博臣 : 前立腺癌密封小線源療法後のPSA failure 症例の臨床的検討, 日本泌尿器科学会総会, 2011年4月.
106.	井崎博文, 高橋正幸, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 福森知治, 金山博臣 : いかに泌尿器科入局者を増やすか!地方大学の卒前教育の取り組み, 日本泌尿器科学会総会, 2011年4月.
107.	中逵弘能, シーレンヤンバアビルメド, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : HGFによる膀胱がん浸潤亢進におけるToll like receptor 4 (TLR4) の関与, 日本泌尿器科学会総会, 2011年4月.
108.	高橋正幸, 河野裕明, 村上佳秀, 須藤泰史, 稲井徹, 布川朋也, 武村政彦, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 去勢抵抗性前立腺癌に対する抗アンドロゲン剤抗体療法とUFT併用療法の有効性と安全性に関する無作為化第Ⅱ相臨床試験, 日本泌尿器科学会総会, 2011年4月.
109.	岸本大輝, 上野恵輝, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣, 香川征 : 非虚血性持続勃起症の1例, 日本性機能学会東部総会, 2011年3月.
110.	山口邦久, 津田恵, 布川朋也, 武村政彦, 山本恭代, 中逵弘能, 岸本大輝, 高橋正幸, 福森知治, 金山博文 : 前立腺癌長期分泌療法施行術における治療中止後のPSAおよびテストステロン値の検討, 中国四国前立腺疾患研究会, 2011年2月.
111.	武村政彦, 津田恵, 布川朋也, 山口邦久, 中逵弘能, 山本恭代, 岸本大輝, 井崎博文, 福森知治, 高橋正幸, 金山博臣 : 2010年徳島大学病院泌尿器科臨床統計, 日本泌尿器科学会四国地方会, 2011年1月.
112.	上野恵輝, 岸本大輝, 津田恵, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 非虚血性持続勃起症の一例, 日本泌尿器科学会四国地方会, 2011年1月.
113.	津田恵, 岸本大輝, 武村政彦, 布川朋也, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 高橋正幸, 金山博臣 : 射精障害を契機に発見された汎下垂体機能低下症の1例, 西日本泌尿器科, Vol.72, 121, 2010年11月. (キーワード) Cortisone(治療的利用)
114.	山本恭代, 津田恵, 布川朋也, 武村政彦, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 高橋正幸, 金山博臣, 田上隆一, 西谷真明 : 徳島大学病院における膀胱水圧拡張術を施行した間質性膀胱炎の検討, 西日本泌尿器科, Vol.72, 169, 2010年11月. (キーワード) 拡張法
115.	武村政彦, 布川朋也, 山口邦久, 中逵弘能, 山本恭代, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 206, 2010年10月.
116.	中逵弘能, 井崎博文, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 岸本大輝, 高橋正幸, 福森知治, 金山博臣 : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 248, 2010年10月. (キーワード) 血液透析
117.	岸本大輝, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 249, 2010年10月.
118.	井崎博文, 高橋正幸, 布川朋也, 武村政彦, 山口邦久, 中逵弘能, 山本恭代, 岸本大輝, 福森知治, 金山博臣 : 転移性副腎腫瘍に対する腹腔鏡手術議論のポイント, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 162, 2010年10月. (キーワード) 腎細胞癌(転移性,外科的療法)
119.	中逵弘能, 井崎博文, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 岸本大輝, 高橋正幸, 福森知治, 金山博臣 : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 24 Endourology ESWL, Vol.23, No.3, 248, 2010年10月. (キーワード) *血液透析
120.	岸本大輝, 布川朋也, 武村政彦, 山本恭代, 山口邦久, 中逵弘能, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, 24 Endourology ESWL, 2010年10月. (キーワード) 精嚢
121.	布川朋也, 松尾泰佑, 三木恒治, 中村祐輔, 金山博臣, 片桐豊雅 : 腎細胞癌新規分子標的候補遺伝子RCCMPの同定およびその機能解析, 第69回日本癌学会学術総会, 2010年9月.
122.	中逵弘能, シーレンヤンバアビルメード, 布川朋也, 高橋正幸, 福森知治, 金山博臣 : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本癌学会学術総会, 2010年9月.
123.	津田恵, 布川朋也, 武村政彦, 山本泰代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : BCG膀胱内注入療法後に生じたReiter症候群の1例, 日本泌尿器科学会四国地方会, 2010年7月.
124.	武村政彦, 津田恵, 布川朋也, 山本泰代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, 日本泌尿器科学会四国地方会, 2010年7月.
125.	井崎博文, 布川朋也, 小泉貴裕, 山本恭代, 中逵弘能, 山口邦久, 岸本大輝, 高橋正幸, 福森知治, 奈路田拓史, 木内慎一郎, 高橋久弥, 赤沢誠二, 武村政彦, 林秀樹, 水田耕司, 橋本寛文, 榊学, 浜尾巧, 金山博臣 : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 日本透析医学会雑誌, Vol.43, No.Suppl.1, 370, 2010年6月.
126.	福森知治, 中逵弘能, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 金山博臣 : 高齢者に対する前立腺癌密封小線源療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.23, 75, 2010年5月. (キーワード) *近距離照射治療法
127.	高橋正幸, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 当科における80歳以上の腎腫瘍患者の臨床的検討, 第23回日本老年泌尿器科学会, 2010年5月.
128.	高橋正幸, 山本洋之, 湯浅明人, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 進行性腎癌に対するNeoadjuvant療法進行性腎癌に対するNeoadjuvant療法のUpdate, 日本泌尿器科學會雜誌, Vol.101, No.2, 152, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205072211840 (CiNii: 1390001205072211840)
129.	高橋正幸, 山本洋之, 湯浅明人, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : DOUBLE-PHASE HELICAL CTによる腎腫瘍組織型予測, 日本泌尿器科學會雜誌, Vol.101, No.2, 214, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205073840256 (CiNii: 1390001205073840256)
130.	福森知治, 中逵弘能, 山本洋之, 湯浅明人, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 金山博臣 : I-125前立腺癌密封小線源療法後の排尿障害の予測因子の検討, 日本泌尿器科學會雜誌, Vol.101, No.2, 242, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390282680048519296 (CiNii: 1390282680048519296)
131.	アビルメッドシーレブニヤンバ, 上原久典, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 泉啓介, 金山博臣 : 骨芽細胞との直接接触による前立腺癌細胞の遺伝子発現変化, 日本泌尿器科學會雜誌, Vol.101, No.2, 369, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390001205072421504 (CiNii: 1390001205072421504)
132.	小泉貴裕, 山本洋之, 湯浅明人, 布川朋也, 山口邦久, 山本恭代, 中逵弘能, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 転移を有さない再燃前立腺癌に対する放射線療法の検討, 日本泌尿器科學會雜誌, Vol.101, No.2, 448, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390282680047830912 (CiNii: 1390282680047830912)
133.	中逵弘能, アビルメッドシーレブニヤンバ, 湯浅明人, 山本洋之, 布川朋也, 小泉貴裕, 山本恭代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 膀胱癌浸潤におけるプラコフィリン2の関与, 日本泌尿器科學會雜誌, Vol.101, No.2, 527, 2010年4月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1390282680050442240 (CiNii: 1390282680050442240)
134.	中逵弘能, Avirmed Shiirevnyamba, 湯浅明人, 山本洋之, 布川朋也, 小泉貴裕, 山本泰代, 山口邦久, 岸本大輝, 井崎博文, 高橋正幸, 福森知治, 金山博臣 : 膀胱がん浸潤におけるプラコフィリン2の関与, 泌尿器科分子・細胞研究会, 2010年2月.
135.	岸本大輝, 山本洋之, 湯浅明人, 布川朋也, 小泉貴裕, 山本泰代, 山口邦久, 中逵弘能, 井崎博文, 福森知治, 金山博臣, 細川忠宣 : 2009年徳島大学泌尿器科臨床統計, 日本泌尿器科学会四国地方会, 2010年1月.
136.	湯浅明人, 山本洋之, 布川朋也, 小泉貴裕, 山本泰代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 回腸導管より出血を繰り返したストーマ静脈瘤の1例, 日本泌尿器科学会四国地方会, 2010年1月.
137.	山本洋之, 高橋正幸, 湯浅明人, 布川朋也, 小泉貴裕, 山本泰代, 山口邦久, 中逵弘能, 岸本大輝, 井崎博文, 福森知治, 金山博臣 : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本泌尿器科学会四国地方会, 2010年1月.

その他・研究会:

1.	楠原義人, 大豆本圭, 尾崎啓介, 津田恵, 森英恭, 布川朋也, 山本恭代, 山口邦久, 福森知治, 高橋正幸, 金山博臣 : ロボット支援腹腔鏡下腎盂形成術の初期経験, 第26回中国四国前立腺・腎尿路疾患研究会, 2018年3月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

患者由来癌組織を用いたRCC Precision Medicine Project (研究課題/領域番号: 23K08736 )
がん由来エクソソームによる筋細胞内代謝制御の解明とがん悪液質の克服 (研究課題/領域番号: 23K06613 )
筋組織内代謝変化を標的としたがん悪液質新規治療法の開発 (研究課題/領域番号: 19K07731 )
エキソソームを介した筋萎縮発症機序の解明と新たな治療へのアプローチ (研究課題/領域番号: 19H03516 )
泌尿器癌の進展におけるガレクチンー３の分子機構の解明と治療応用 (研究課題/領域番号: 18K09136 )
研究者番号（70564342）による検索

講師 : 布川朋也

研究活動

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

講師 : 布川 朋也

研究活動

専門分野

研究テーマ

著書・論文

著書:

学術論文(審査論文):

学術論文(紀要・その他):

総説・解説:

国際会議:

国内講演発表:

その他・研究会:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

講師 : 布川朋也